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Glaucoma is a disease with characteristic optic nerve damage and vision loss.  It is the 
leading cause of irreversible blindness affecting more than 60 million people worldwide. 
Glaucoma affects the quality of life in older populations and has significant public health and 
economic consequences for society, making it a critical public health problem.  The established 
risk factors for the development of open-angle glaucoma (POAG), the most common type of 
glaucoma, are mostly non-modifiable such as age, family history, gender, race, myopia and 
other anatomical eye characteristics. Elevated IOP is the only modifiable and key determinant 
of POAG. Reducing IOP levels decreases the incidence and progression of glaucoma compared 
with no treatment, even in normal-tension glaucoma.  
Traditional cardiovascular risk factors (hypertension, diabetes, body mass index) were 
suggested to influence IOP and the development of POAG. However, previous literatures were 
limited by cross-sectional design, small sample size and inconsistent results. The main 
objective of this study is to access the longitudinal association of cardiovascular risk factors 
with IOP trajectories, and to quantitatively synthesize the association between these risk factors 
and the risk of POAG. 
First, we conducted a systematic review of the available literature on the association 
between blood pressure levels and hypertension with primary open-angle glaucoma and 
intraocular pressure endpoints. Sixty observational studies were eligible and included in the 
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final meta-analysis. High blood pressure was associated with increased IOP and higher risk of 
POAG. 
Second, we conducted another systematic review of the available literature on the 
association of diabetes and blood glucose levels with glaucoma, intraocular pressure (IOP) and 
ocular hypertension in the general population. Forty-seven studies including 2,981,342 
individuals from 16 countries were included in the final meta-analysis. Diabetes, diabetes 
duration, and fasting glucose levels were associated with a significantly increased risk of 
glaucoma, and diabetes and fasting glucose levels were associated with slightly higher IOP.   
Third, we conducted a cross-sectional analysis of 3,299 adults from 2005-2008 
NHANES, to investigated the association between diabetes, pre-diabetes, metabolic syndrome 
and its components and the levels of fasting glucose, HbA1c and HOMA-IR with the 
prevalence of glaucoma. Diabetes was associated with higher risk of glaucoma.  We also found 
hockey-stick shaped associations between biomarkers of glucose metabolisms and the 
prevalence of glaucoma. 
Fourth, we examined the longitudinal association between age and IOP in a prospective 
cohort study of 274,064 adult men and women who underwent a screening examination 
between January 2011 and December 2013 at the Kangbuk Samsung Total Healthcare Center 
in Seoul and Suwon, South Korea. IOP was inversely associated with age in this population, 
and the association was stronger in men compared with women. 
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Finally, we examine the longitudinal and cross-sectional associations between body 
mass index (BMI), waist circumference, percent fat mass and IOP in the same population of 
274,064 Korean men and women. All body adiposity markers were positively associated with 
increased IOP in both longitudinal and cross-sectional fashion, and the association was more 
evident in central obesity represented by waist circumference. 
In conclusion, hypertension and diabetes are risk factors for POAG and elevated IOP in 
the general population. IOP decreased over time with age in Korean adults, and baseline and 
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ANATOMY AND PHYSIOLOGICAL DETERMINANTS OF GLAUCOMA 
AND INTRAOCULAR PRESSURE (IOP) 
Aqueous humor, the fluid that fills the front of the eye, is produced by the ciliary body 
within the posterior chamber of the eye and flows through the pupil into the anterior chamber. 
Aqueous humor exits the eye by filtering through the trabecular meshwork into the Canal of 
Schlemm and returns back to the blood circulation. The IOP is maintained by this steady state 
of aqueous humor production and outflow. Inadequate outflow or overproduction of inflow can 
result in increased intraocular pressure (IOP) and vision loss. Glaucoma is primarily a disorder 
of aqueous humor physiology. With prolonged high IOP, the ganglion cells are injured 
resulting in gradual vision loss. 
GLAUCOMA EPIDEMIOLOGY 
Glaucoma is a disease with characteristic optic nerve damage and vision loss. It is 
responsible for 14% of blindness globally,1 and is the second leading cause of blindness in the 
United States (US).  Primary open-angle glaucoma (POAG), which accounts for at least half of 
all glaucoma cases, affects more than 2.2 million persons in the US, and this number is 
projected to increase to 3.4 million in 2020.2 Among US Whites, POAG is present in 0.3 – 4.0 % 
of people aged over 40. In Asian populations, POAG is present in 0.5 to 2.6% of the people 
aged over 40.3 Other types of glaucoma include angle-closure glaucoma (ACG), congenital 
glaucoma and secondary glaucoma. About 10% of all individuals with glaucoma are estimated 





RISK FACTORS FOR GLAUCOMA  
Age: Population-based studies consistently show an exponential rise in the prevalence and 
incidence rates with increasing age. In the Barbados Eye Study6 and the Rotterdam study,7 
there was a 4% and a 6% increased risk of developing POAG with each year of age increase, 
respectively. In the Visual Impairment Project in Australia, subjects aged 70–79 years at 
baseline had a 12-fold increased 5-year risk of developing POAG compared to subjects aged 
40–49 years old.8  
Race: In general, the prevalence of POAG is highest in African American populations; 
intermediate in non-Hispanic Whites, Hispanics, and southern Asian populations (Singapore 
Chinese, Indian); and lowest in northern Asian populations.9  
Genetic factors: Family history of glaucoma is an important risk factor. Having a first-
degree relative with glaucoma has been consistently associated with an increased risk for 
POAG in prevalence surveys, and it is estimated that siblings of affected individuals have 
nearly an 8-fold risk of POAG when compared to siblings of unaffected individuals.7,10  
CVD risk factors: Cardiovscular diseases, such as diabetes and hypertension, can cause 
microvascular damage and may affect vascular autoregulation of the retina and optic nerve.11 
Vascular damage can reduce blood flow and impair oxygen diffusion. Endothelial cell injury 
and dysfunction can reduce the autoregulatory capacity to protect against fluctuations of IOP, 
which could lead to relative hypoxia and to damage of the optic nerve head and of the retinal 
nerve fiber layer.12 
Intraocular pressure (IOP): Elevated IOP level is a major risk factor for the development 
and progression of POAG, and lowering the IOP in patients suffering from POAG slows up the 




IOP damages the sensitive optic nerve and results in vision loss14. However, there is no 
threshold at which the IOP value is defined as dangerous, as people have different 
susceptibility and vulnerability of the optic nerve head to a particular IOP level9. In addition, 
there is a racial difference in the degree to which elevated IOP causes POAG. Only 5.4% of 
whites with ocular hypertension (IOP>21 mmHg) progress to POAG, while 18.1% of blacks 
with ocular hypertension progress to POAG.15 
IOP EPIDEMIOLOGY 
Average IOP varies with different ethnic groups. The mean IOP (± standard deviation [SD]) 
value in the general population in US is approximately 15.5 ± 2.57 mm Hg, following a 
Gaussian distribution16. Normal intraocular pressure is considered between 10 mmHg and 21 
mmHg. An IOP >21 mmHg is often referred to as ocular hypertension3. 
RISK FACTORS FOR IOP 
Age: Age is considered a significant factor for progression of intraocular pressure (IOP) 
and incidence of ocular hypertension (OHT). However, the direction of correlation is not 
consistent throughout previous population-based studies. In studies composed of Caucasians, 
blacks or Irish populations, a positive correlation between increasing age and IOP is reported17–
23. In contrast, an inverse relationship of age and IOP is generally reported in Asian populations. 
IOP is found to decrease with age in cross-sectional studies and one longitudinal study in 
Japan24–27. 
Blood pressure: Several population based studies have consistently reported cross-




with higher IOP28–31. The positive correlation between systolic blood pressure (SBP), diastolic 
blood pressure (DBP) and IOP observed in both healthy individuals and OAG patients also 
appears to be present across all races. However, the actual change in IOP with increasing BP is 
relatively small. In cross-sectional studies, each 10 mm Hg increment in SBP leads to a mean 
of 0.23 to 0.32 mm Hg rise in IOP, and each 10mm Hg increment in DBP leads to a mean of 
0.19 to 0.55 mm Hg rise in IOP. In longitudinal analysis of Beaver Dam Study, each 10 mm Hg 
increase in SBP from baseline leads to a 0.21 mm Hg rice in IOP over a 5-year interval. If we 
assume that the mean IOP at baseline is 15 mm Hg, then the change is about 1.4% over a 5 year 
interval. 
Central corneal thickness: Measurement of IOP is subject to the influence of central 
corneal thickness. The general procedures of IOP measurement require placing the tip of 
tonometry equipment against the cornea; the IOP is read by configure the appropriate amount 
of force to flattening or indenting the cornea. Thee principle is that IOP is proportional to the 
force required to flatten a defined area of cornea. Thin cornea leads to underestimation of true 
IOP while thick cornea leads to falsely higher pressure readings3 
Diabetes: Several cross-sectional studies have documented that populations with high 
prevalence of diabetes or raised blood glucose level have an increased risk of elevated IOP32,33. 
One study also found that a number of metabolic abnormalities related to insulin resistance 
were associated with elevated IOP34. In addition, several cross-sectional studies have 
documented a correlation between elevated blood glucose or HbA1c levels and raised IOP in 
diabetic patients11,29,35,36. 
Obesity: Previous cross-sectional studies have consistently shown that obesity and 




factor for higher IOP, BMI may have a U-shaped association with glaucoma32. The U shape 
could be related to the fact that underweight individuals may be more likely to have chronic or 
infectious disease, which may affect their susceptibility to ocular hypertension. Potential 
mechanisms include excess intraorbital fat tissue, increased episcleral venous pressure, and 
increased blood viscosity with increased outflow resistance of episcleral veins. These factors 
could result in decreased in outflow facility. Another study suggested that the breath holding 
and thorax compression while tonometry is performed at the slitlamp on obese patients may 
cause transitory elevations of IOP, thus increase IOP readings using Goldmann tonometer 41. 
SIGNIFICANCE 
Glaucoma accounts for 9% to 12% of all cases of blindness in the U.S5. High IOP is the 
most important risk factor for primary pen-angle glaucoma, which accounts for >50% 
glaucoma cases. Since open-angle glaucoma is a chronic condition, it must be monitored for 
life, which makes IOP a key component of regular eye examination. Ocular hypertension is 
common in the elderly. About 2% of the population ages 40-50 and 8% over 70 have ocular 
hypertension. The prevention of ocular hypertension and IOP control have public health 
significance in reducing incidence and progression of glaucoma. However, the underlying 
mechanism for cardiovascular risk factors to impact ocular pressure remains elusive. Our study 
will delve into both traditional and non-traditional CVD risk factors and explore the correlation 
between those risk factors and the progression of IOP. Both identification and summation of 
the CVD risk factors need to be characterized to reach an assessment of people at risk of 





INNOVATION OF THIS THESIS 
Figure 1. Conceptual framework for CVD risk factors with glaucoma and IOP 
 
Identifying potential modifiable risk factors can has important implication in glaucoma 
prevention and improvement of prognosis. However, current studies on the CVD risk factors 
were limited by cross-sectional design, small sample size, or highly selective population. The 
cross-sectional studies were incapable of establishing temporality, while the few longitudinal 
studies reported conflicting results. With regard to the gap in previous literatures, the objective 
of this thesis is to first summarize and quantitatively synthesize available literature on the 
association of CVD risk factors with the risk of glaucoma and IOP, and then investigate the 
longitudinal association of CVD risk factors with IOP trajectories using the Kangbuk Samsung 
cohort study. 
Our study has several strengths compared with previous studies. Our cohort study is by 
far the largest population-based cohort study evaluating the longitudinal association between 
CVD risk factors and IOP. Our longitudinal design enables us to be less affected by biases 
commonly seen in cross-sectional studies. We also adopted three-level hierarchical approach to 
appropriately account for correlations between eyes and between visits for each participant. 
In the following chapters, we would like to individually evaluate the association of 
CVD risk factors, including hypertension, diabetes, age and BMI, with glaucoma and IOP 




risk for glaucoma and IOP. (Figure 1) In addition, we hypothesize that IOP may decrease with 
age, which was suggested in most of the previous cross-sectional studies based on Asian 
population. Our study contributes to the understanding of IOP and glaucoma mechanism, and 
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Objective: To conduct a systematic review and meta-analysis of the association between blood 
pressure levels and hypertension with primary open-angle glaucoma and intraocular pressure 
endpoints. 
Clinical Relevance: Blood pressure is a potentially modifiable risk factor that may contribute 
to intraocular hypertension and glaucoma risk, but individual studies of the association between 
hypertension and glaucoma have been inconsistent. 
Design: Systematic review with quantitative meta-analysis. 
Methods: Studies were identified by searching the PubMed and EMBASE databases. Inverse-
variance weighted random-effects models were used to summarize relative risks. Subgroup 
analyses and meta-regression were used to explore potential sources of heterogeneity across 
studies. 
Results: Sixty observational studies were included. The pooled relative risk for primary open-
angle glaucoma comparing patients with hypertension to those without hypertension was 1.16 
(95% CI= 1.05-1.28), with modest heterogeneity across studies (I2 34.5%). Virtually all studies 
reported a positive association between blood pressure and intraocular pressure. The pooled 
average increase in IOP associated with a 10 mmHg increase in SBP was 0.26 mmHg (95% CI 
0.23 – 0.28, I2 30.7%), and the average increase associated with a 5 mmHg increase in DBP 
was 0.17 mmHg (95% CI 0.11 – 0.23, I2 90.5%). 
Conclusions: In this meta-analysis, hypertension was associated with increased intraocular 
pressure. The association between hypertension with primary open-angle glaucoma was 




support a role of increased blood pressure in elevated intraocular pressure and possibly in the 
development of glaucoma. 
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Glaucoma is the leading cause of irreversible blindness affecting more than 60 million 
people worldwide.1 The risk and prognosis of primary open-angle glaucoma (POAG), the most 
common type of glaucoma, is influenced by demographic factors such as age, race and family 
history, and by several ocular parameters including myopic refractive error, optic disc shape 
and corneal thickness.2–4 Increased intraocular pressure (IOP) is the most important modifiable 
risk factor for POAG,5,6 but there is substantial interest in identifying other potentially 
modifiable risk factors.  
Systemic hypertension may contribute to increased IOP via overproduction or impaired 
outflow of aqueous humor.7,8 Some,9–14 but not all15–19 population studies have found 
statistically significant positive associations between systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) with IOP. Furthermore, the literature on the association between 
blood pressure (BP) and POAG is limited and inconsistent.20–23 Qualitative reviews have 
summarized the evidence on BP, IOP and glaucoma,7,24,25 but these reviews did not conduct 
systematic searches of the literature to incorporate all relevant studies and did not produce 
quantitative estimates of the associations. In addition, most studies included in these reviews 
were published before 2005. The objective of this meta-analysis was thus to summarize and 
quantitatively synthesize available literature on the association of BP with IOP and POAG. 
MATERIALS AND METHODS 
Search Strategy 
Our systematic review and meta-analysis was conducted according to the Meta-analysis 




we searched MEDLINE and EMBASE for observational studies investigating the relation of 
BP or hypertension with POAG, IOP or ocular hypertension (OHT) with no restrictions on 
language or publication date. The search period was through April 2013. Key words included 
systolic blood pressure, diastolic blood pressure, blood pressure, hypertension, intraocular 
pressure, intraocular tension, eye pressure, eyeball pressure, eye internal pressure, intraorbital 
pressure, ocular pressure, ocular tension, intraocular hypertension, intraocular tension, and 
glaucoma. In addition, we manually reviewed the reference lists from relevant original research. 
Study Selection  
We aimed to identify all relevant observational studies that assessed the association of 
BP or hypertension with IOP, OHT or POAG in general population settings. We applied the 
following exclusion criteria: (1) reviews, editorials, or letters; (2) case reports or case series; (3) 
studies not conducted in humans; (4) studies not conducted in adults; (5) studies conducted in 
population samples comprised only of patients with established glaucoma or ocular 
hypertension at baseline; (6) studies not reporting glaucoma, IOP or OHT outcomes; (7) studies 
not using BP or hypertension as exposure; (8) studies investigating mainly drug effects or 
metabolism; (9) and studies of populations with specific conditions (e.g., pregnancy or eye 
surgery) that limit their generalizability to general population samples. Furthermore, since age 
is a strong risk factor for glaucoma and for hypertension development, we further excluded 
studies that did not adjust for age in the design or the analysis.  
For studies that did not report POAG separately from other types of glaucoma, we used 
results for open angle glaucoma or glaucoma as endpoints. For studies that reported both cross-
sectional associations at baseline and prospective longitudinal associations, we included both 




within a study population, we selected the publication with the largest sample size or the 
longest follow-up. Several studies reported estimates of measures of association without 
standard errors or any other estimates of statistical variability. These studies were included in 
the systematic review, but were excluded from the quantitative meta-analysis. 
Data Extraction and Quality Assessment 
Two investigators (D.Z and M.K.) independently reviewed all search results to identify 
eligible papers and abstracted data from selected articles, including study design, study 
population, age and sex distribution, sample size, study outcomes, duration of follow-up, 
exposure and outcome assessment, main results, and variables included in the adjusted model. 
Discrepancies between reviewers were solved by consensus. We assessed the risk of bias in 
studies using the methods described by Sanderson et al27 and Viswanathan et al.28 We 
examined the methods for selecting study participants, the criteria for defining exposures and 
outcomes, the risk of bias associated with different designs, the methods used to control for 
confounding, and potential conflicts of interest. 
Statistical Analysis 
The study endpoints were POAG, IOP, and OHT. We used as many endpoints as 
reported in each study and conducted separate meta-analyses for each end point (Table 1). For 
hypertension, we combined hazard ratios, odds ratios, and relative risks for POAG or OHT 
comparing participants with vs. those without hypertension, and average differences in IOP (in 
mmHg) comparing participants with vs. those without hypertension. For SBP and DBP, we 
combined hazard ratios, odds ratios or relative risks for POAG or OHT associated with an 




mmHg) associated with an increase in 10 mmHg for SBP and in 5 mmHg for DBP. These 
measures of association and their 95% confidence intervals (CIs) were abstracted or derived 
from published data. For studies reporting standardized regression coefficients, we used the 
standard deviations for BP and IOP reported for that population to recalculate unstandardized 
regression coefficients. Finally, for studies reporting measures of association based on log-
transformed SBP or DBP, we calculated the measures of association based on 10 and 5 mmHg 
increases in SBP or DBP, respectively, calculated from the population mean.   
When several models for a given endpoint were reported in the same study, we selected 
the maximally adjusted model. For studies reporting results separately by subgroups (e.g., men 
and women, hypertension with and without medication, hypertension only and with other 
diseases, or participants from different locations), we used each group as an independent result 
for the meta-analyses. For studies reporting both overall and subgroup results, we used overall 
estimates.  
We used DerSimonian and Laird's random-effects models to calculate summary relative 
risks across studies. Between-study heterogeneity was quantified using the I2 statistic, which 
describes the proportion of total variation in study estimates due to heterogeneity. We also 
assessed the relative influence of each study by omitting one study at a time from the pooled 
analysis. Publication bias was evaluated using funnel plots and Egger's tests. The funnel plots 
depict the distribution of the measures of association vs. their standard errors. The null 
hypothesis of Egger's test is that the regression of measures of association over their standard 
error has an intercept of zero. The rejection of the null hypothesis (p < 0.05) suggests that the 
measures of association depend on the study sample size, which may reflect publication bias.29 




study type (case-control, cross-sectional, longitudinal), location (Europe, America, Asia, 
others), and year of publication (<2000, ≥2000) using meta-regression with restricted 
maximum likelihood estimates of between-study variance. We did additional meta-regression 
by adjustment for IOP (Yes, No) and adjustment for central corneal thickness (Yes, No). 
Studies presenting measures of association for BP in 3 or more categories or as 
continuous exposures were also combined using a random-effects dose-response meta-analysis 
as described by Greenland and Longnecker.30,31 One study reporting the dose-response 
association between BP and POAG was excluded because of the small number of POAG cases 
in each BP interval.32 All statistical analyses were conducted with Stata version 12 (STATA 
Corp, College Station, TX). 
RESULTS 
Study Characteristics 
We identified 60 studies (44 cross-sectional, 9 case-control, and 7 longitudinal cohort 
studies) that met our inclusion criteria (Figure 1, Supplemental Table 1). Twenty-six studies 
were performed in Asia, 13 in the US, 9 in Europe, 3 in the West Indies, 3 in Australia, 3 in 
Canada, 2 in the Middle East, and 1 in Congo. The prevalence of POAG in cross-sectional 
studies ranged from 0.7% to 9%. The number of studies that presented quantitative estimates 
and 95% CIs that could be incorporated our meta-analysis was 29 for POAG (27 with estimates 
for hypertension, 10 for SBP and 8 for DBP), 5 for OHT (4 with estimates for hypertension, 1 
for SBP and 1 for DBP), and 18 for IOP (3 for hypertension, 17 for SBP and 14 for DBP). 
POAG, open angle glaucoma and glaucoma criteria differed across studies. To identify 




chamber angle, optic nerve damage or visual field changes, 14 studies also considered OHT as 
an additional criteria, 2 studies used self-reported glaucoma, 1 study used medical history 
records, and 1 study used ICD-9 codes from a medical database. Among the studies that 
assessed the association between BP and IOP, five measured IOP using a Goldmann 
applanation tonometer, while the rest used non-contact tonometers, Schiotz tonometers, or 
handheld tonometers. The average IOP of the study populations ranged from 11.5 to 16.1 mm 
Hg (Table 1). For studies reporting OHT as an outcome, 1 study defined OHT as IOP > 20 
mmHg, 1 as IOP ≥ 21 mmHg, 3 as IOP > 21 mmHg. The studies also differed in their 
definition and ascertainment methods for hypertension (Supplemental Table 2), and in the 
covariates adjusted for (Supplemental Table 3).  
Primary open angle glaucoma 
The association between hypertension and POAG was heterogeneous across studies. 
Eighteen studies reported a positive association while 9 studies reported an inverse or null 
association. Seven studies adjusted for IOP and two studies adjusted for central corneal 
thickness (CCT) in their analysis. The pooled relative risk (RR) for POAG comparing 
participants with vs. those without hypertension was 1.16 (95% CI 1.05 – 1.28), with modest 
across study heterogeneity (I2 34.5%) (Figure 2). The pooled RR was significant for cross-
sectional studies (1.24, 95% CI 1.06 – 1.44) but it was smaller and not statistically significant 
for case-control (1.08, 95% CI 0.92 – 1.28) and longitudinal studies (1.05, 95% CI 0.69 – 1.59), 
although only two longitudinal studies contributed to the pooled estimates. The overall pooled 
RR in sensitivity analysis based on studies that defined POAG without using IOP as a 
diagnostic criterion was 1.14 (1.03 – 1.25, I2 24.0%). In dose-response meta-analysis of studies 




exposure, the pooled RR for POAG associated with a 10 mm Hg increase in SBP was 1.01 (95% 
CI 1.00 – 1.03, I2 26.1%) and the pooled RR associated with a 5 mm Hg increase in DBP was 
1.02 (95% CI 0.99–1.04, I2 25.9%) (Figure 3).  
Intraocular pressure 
Virtually all studies reported a positive association or correlation between SBP, DBP 
and IOP (Figure 4, Supplemental Table 4). The pooled average increase in IOP associated 
with a 10 mmHg increase in SBP was 0.26 mmHg (95% CI 0.23 – 0.28, I2 42.5%), and the 
average increase associated with a 5 mmHg increase in DBP was 0.17 mmHg (95% CI 0.11 – 
0.23, I2 91.2%), with similar results in cross-sectional compared to longitudinal studies. The 
pooled average difference in IOP comparing participants with vs. those without hypertension 
was 0.33 mm Hg (95% CI 0.25 – 0.40, I2 0%), although this estimate was based only on three 
studies (Figure 5). 
Only 4 studies assessed the relation between hypertension and OHT, and 3 of these 
studies were published before 1990. The pooled RR for OHT comparing participants with and 
without hypertension was 1.26 (0.79 – 2.02, I2 82.2%) (Figure 6). The association between BP 
levels and OHT was evaluated only in one nested case-control study15 in which SBP was higher 
but DBP was not significantly different in OHT cases compared with controls.  
Excluding individual studies did not substantially affect the estimates for most 
associations. The pooled RR estimates after leaving out one study at a time ranged from 1.14 to 
1.18 for POAG comparing participants with vs. those without hypertension; from 1.001 to 1.01 
for POAG associated with an increase in 10 mmHg of SBP; from 1.004 to 1.01 for POAG 
associated with an increase in 5 mmHg of DBP; and from 0.99 to 1.44 for OHT comparing 




one study at a time ranged from 0.24 to 0.26 mmHg per an increase in 10 mmHg of SBP; from 
0.15 to 0.18 mmHg per an increase in 5 mmHg of DBP; and from 0.32 to 0.36 mmHg 
comparing participants with vs. those without hypertension. Egger's tests for publication bias 
were statistically significant for SBP (p < 0.001), hypertension and IOP (p = 0.045). Funnel 
plots suggested that small studies were reporting stronger associations compared to larger 
studies, but even large studies reported positive associations. (Supplemental Figure 1) All 
studies adjusted for age, but only one study adjusted for age, IOP and CCT at the same time 
(Vijaya, 2008). For the association between hypertension and POAG, seven studies adjusted for 
IOP and two studies adjusted for CCT. The associations between the exposures and outcomes 
were similar among different types of studies, countries, adjustment for IOP and CCT, and year 
of publication (p > 0.05), except for SBP and IOP, as well as SBP and POAG, where the 
estimate was lower in longitudinal studies compared with cross-sectional studies.  
DISCUSSION 
In this comprehensive meta-analysis, hypertension and increased SBP and DBP were 
consistently associated with increased IOP across published studies. Hypertension was also 
positively associated with the risk of POAG, although the association was significant in cross-
sectional but not in case-control or longitudinal studies. The dose-response relationship 
between SBP and DBP and the risk of glaucoma was also positive but weak. On the other hand, 
our findings support a role of increased BP in elevated IOP and possibly in the development of 
POAG. 
Several mechanisms may explain an increase in IOP with higher BP. Increasing BP may 
result in increased production of aqueous humor by means of elevated capillary pressure in the 




pressure.34 Indeed, the sympathetic nervous system and the renin-angiotensin system may be 
involved in the autoregulation of aqueous humour formation, outflow and BP.24 Experimental 
models in animals also support a role of BP in IOP levels. Rapid bleeding resulted in a 
reduction of rate of aqueous formation in monkeys.24 Angiotensin II receptor blockers (ARB) 
and angiotensin-converting-enzyme (ACE) inhibitors, which are used for the treatment of 
hypertension, lower IOP in animals and humans.35–37 Increased IOP may also mediate the 
association between BP and POAG, although direct micro-vascular damage caused by 
hypertension may impact blood perfusion to the optic nerve and cause ganglion cell injury 
irrespective of IOP levels.38  
While the association of hypertension with IOP was consistent across studies, the 
association of hypertension with POAG showed significant heterogeneity, and the dose-
response association of BP with POAG was weak. Indeed, a number of studies have found a 
higher risk of POAG in participants with low BP, 39,40 and a high prevalence of low BP in 
normal tension glaucoma.41,42 It has been hypothesized that both hypertension and hypotension 
are risk factors for POAG.43 Low BP may compromise the autoregulation of the ciliary artery 
circulation, impair blood flow to the optic disc, and induce glaucomatous damage.41,44 In our 
meta-analysis, several studies showed a J-shaped association between BP and POAG (Figure 
3). Unfortunately, many studies conducted their analyses assuming a linear dose-response 
relationship between BP and POAG, and even for studies not assuming linear dose-response 
relationships, meta-analyses are limited to identify complex dose-response relationships. A J-
shaped relation between BP and POAG could explain both the heterogeneity in the association 
between hypertension and POAG and the small magnitude of the association between BP and 




between BP with POAG should report detailed dose-response relationships and avoid using 
methods that assume a linear association. 
The positive associations of BP and hypertension with IOP were robust across studies 
conducted in many different settings and with adjustment for a variety of confounders. We 
attempted to limit the influence of uncontrolled confounders on this meta-analysis by excluding 
studies that did not adjust for age. Furthermore, the magnitude and direction of the associations 
did not differ with different degrees of adjustment, suggesting that the results of this meta-
analysis were robust to misspecification of known confounders in the analysis. Furthermore, a 
number of clinical trials and hospital-based studies have supported that antihypertensive 
medications including calcium-channel blockers, diuretics, ACE inhibitors and β-blockers, 
administrated either topically or orally, can reduce IOP and slow progression to glaucoma in 
humans.45–47 The clinical evidence from the effects of antihypertensive medications also 
support a causal relation between hypertension, IOP, and POAG. However, the observational 
evidence between hypertension and POAG summarized in this meta-analysis was largely 
driven by cross-sectional results. Well conducted longitudinal studies are needed to establish 
the role of blood pressure on the risk of glaucoma. 
Aging is an important confounder in the association between BP, IOP and POAG. Since 
BP and age are highly correlated, careful interpretation of the association between BP, IOP and 
POAG should be considered in the context of effect of age. In this meta-analysis, we excluded 
studies that did not adjust for age, considering that aging would be a crucial confounder for the 
association between BP, IOP and POAG. However, it was not possible to account for the 
effects of other age-related risk factors in the current analysis, such as damages of the glial 




We found that both high and low BP were associated with increased risk of POAG. 
While we hypothesized that the increase in BP would be associated with an elevated IOP, 
leading to increased risk of glaucoma, excessive BP lowering in glaucoma patients may cause a 
drop in ocular perfusion pressure (arterial BP minus IOP) and ischemic injury, which was also 
found to be a significant risk factor for glaucoma in large epidemiological studies.48 
Randomized clinical trials also suggested that a low level of BP was associated with risk and 
progression of glaucoma. In the Early Manifest Glaucoma Trial, lower systolic BP in patients 
with lower baseline IOP was associated with faster progression for open-angle glaucoma.49 
However, this J-shape association between systolic and diastolic BP with IOP may by 
confounded by antihypertensive treatment status, as treated or over-treated hypertensive 
patients can have a normal or low BP but they may have elevated POAG risk. In the 
Thessaloniki Eye Study, low diastolic ocular perfusion pressure was associated with increased 
risk for POAG in subjects using antihypertensive treatment.50 However, in our study, 
information on antihypertensive treatment was not available in the original studies, and we 
could not evaluate if the J-shape association was related to use of anti-hypertensive treatment. 
Some limitations of our meta-analysis need to be considered. First, studies differed 
widely in the characteristics of the study populations, the measurement techniques and the 
definitions of BP, IOP, and glaucoma, and the prevalence of pre-existing comorbidities. The 
gold standard for measuring IOP is the Goldmann applanantion tonometer.51 While non-contact 
tonometers are being widely used in many clinical settings for convenience, there were 
concerns about their reliabilty in patients with irregular cornea or poor visual acuity, and they 




sensitivity analysis, however, showed similar associations when the analyses was restricted to 
studies using Goldmann applanantion tonometers.  
Second, most studies measured BP and IOP at a single point in time. Both BP and IOP 
are subject to substantial within-person variability,53 which may result in underestimation of the 
associations. Third, there was also heterogeneity in the measures of association used and in the 
covariates adjusted for in each study and we also cannot exclude the possibility that individual 
study results were affected by uncontrolled residual confounding, such as lifestyle or 
environmental factors. Finally, although the total number of studies was large, there were few 
prospective cohort studies, making it difficult to assess temporality, a key consideration in 
establishing causality.  
In spite of methodological heterogeneity across studies, we identified a consistent and 
robust association between BP and IOP. This association was evident across different 
populations, study designs and publication periods. We also identified a significant association 
between hypertension and POAG, although there was significant heterogeneity across study 
designs. Additional prospective studies are needed to firmly establish the role of blood pressure 
in glaucoma development. Our analysis supports that hypertensive patients should be screened 
for elevated IOP and higher risk for POAG, and that hypertension management be included as 
part of POAG treatment regimes.  
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Cross-sectional            
Leske, 1983 US Framingham Heart Study and Framingham Eye 
Study 
Community 2433 1975 HTN OHT GAT NA NA NA 
David, 1987 Israel Participants from urban areas in southern Israel Health 
screening 
exam 
2594 1984 HTN OHT GAT 40-79 15.0 NA 
Wormald, 
1994 
UK African Caribbean immigrants living in London Community 873 1991 HTN Glaucom
a 





The Rotterdam Study Community 4187 1993 SBP, 
DBP 
IOP GAT 55-95 14.6 NA 
Tielsch, 
1995 
 US The Baltimore Eye Survey Community 5308  1988 SBP, 
DBP, 
HTN 
 POAG NA  >40  NA 3% 
Nomura, 
1999 
Japan Office workers and their family members Health 
screening 
exam 
68998 1997 SBP, 
DBP 
IOP NCT 20-79  11.8 NA 
Bonomi, 
2000 
 Italy The Egna-Neumarkt Study Community 4297  NA HTN  POAG NA  40-
89 
 NA 1.4 
Quigley, 
2001 
US Hispanics in Arizona Community  4774  1990 SBP, 
DBP, 
HTN 
OAG GAT  >40  15.6 2 
Nomura, 
2002 
Japan National Institute for Longevity Sciences–the 
Longitudinal Study of Aging program (NILS-LSA) 
Community 1317 1999 SBP, 
DBP 
IOP NCT 40-80 13.5 NA 
Yoshida, 
2003 
Japan Participants from a general hospital Health 
screening 
exam 







Australia The Blue Mountains Eye Study Community  3654 1994 HTN OAG GAT  66.2  NA 3 
Bai, 2005 China Participants in rural province in China Community 1775 2003 HTN POAG PAT 50 - 
91 
NA NA 
Chen, 2005 Taiwan Hospital based healthy subjects Health 
screening 
exam 
1271 2001 SBP, 
DBP 
IOP NCT 50.0 13.6 NA 
Mitchell, 
2005 
Australia The Blue mountains eye study Community 3302 1994 SBP, 
DBP 
IOP PAT 49- 
97 
NA NA 
Oh, 2005 South 
Korea 
Healthy visitors to health promotion center Health 
screening 
exam 





The Rotterdam Study 
 
Community  5317  1993 SBP, 
DBP 




Vijaya, 2008  India  The Chennai Glaucoma Study Community  3850  2004 HTN  POAG GAT  54.8 15.2 3.5 
Tan, 2009 Singapor
e 
The Singapore Malay Eye Study Community  3280 2006  SBP, 
DBP, 
HTN 
POAG GAT  58.7  NA 3.2 
Wang, 2009 China The Beijing Eye Study Community  3222 2006 HTN POAG NCT 60.4 15.7 2.4 
Chang, 
2010 
Taiwan University Hospital Health 
screening 
exam 
1044 2006 SBP, 
DBP 
IOP NCT 50.8 14.5 NA 
Imai, 2010 Japan General hospital Health 
screening 
exam 
14003 2008 HTN OHT NCT 18-83 14.8 NA 
Memarzade
h, 2010 
US Los Angeles Latino Eye Study Community  6130 2003 SBP, 
DBP 
 OAG GAT 54.7 14.2 4.7 
Park, 2010 South 
Korea 
Kyunggi Province Community 446 2008 SBP, 
DBP 
IOP NCT 41.6 12.4 NA 




 NA 1.5 
Ishikawa, 
2011 
Japan Subjects attending community health screenings Health 
screening 
exam 





Greece Thessaloniki Eye Study Community  2261  1999 HTN  POAG GAT 70.4 15.9 6 
Goldacre, 
2012 
UK Analysis of the Oxford Record Linkage Study 
(ORLS) and English Linked Hospital Episode 
Statistics (LHES) 









Kim, 2012 South 
Korea 
Survey of local residents Community  1464  2006 HTN  POAG GAT 63.7 13.5 3.8 
Lee, 2012 South 
Korea 
Healthy Twin Study Community 3096 2005 SBP IOP NCT 37.8 13.7 NA 
Sun, 2012 China Villagers Community  4956  NA HTN  POAG PAT  >40 14.0 0.7 
Case-control           
Morgan, 
1975 
Canada Cases drawn from University of 
British Columbia, and from a private practitioner 






NA HTN POAG, 
OHT 
NA NA NA NA 
Reynolds, 
1977 





1975 HTN OAG NA ≥18 NA NA 
Wilson, 
1987 
US Patients from General Eye Service(GES) of the 
Massachusetts Eye and Ear Infirmary (MEEI) 





POAG NA NA NA NA 





 94 cases, 
94 controls 















 NA HTN POAG GAT 65.5  NA NA 
Charliat, 
1994 








 1994 HTN POAG GAT 65.7 16.9 NA 
kaimbo, 
2001 









OAG GAT 28-81 19.3 NA 








2000 HTN POAG GAT 32-71 20.6 NA 
Orzalesi, 
2007 








NA HTN POAG GAT 67.2 16.2 NA 
Longitudinal           
Mcleod, 
1990 










Barbados eye study Community 2996 1988, 4 
yr follow-
up 
HTN IOP GAT 57.5 18.4 NA 
Klein, 2005 US Beaver Dam study 
 







60.4 15.4 NA 
Nakano, 
2005 
Japan Male aircraft crew members 
 





IOP GAT 35.9 13.8 NA 
Wu, 2006 West 
Indies 





IOP GAT 55.1 17.5 NA 
Leske, 2008 West 
Indies 






OAG NA 56.9 18.0 NA 
Newman-
Casey, 2011 





HTN  OAG NA 54.5 NA Incidenc
e: 2.5 
*HANES: Health and Nutrition Exam Survey; GAT: Goldmann Applanation Tonometer; ST: Schiotz tonometer; PAT: Perkins applanation tonometer; NCT: Non-
contact tonometer; IOP: Intraocular pressure; POAG: Primary open-angle glaucoma; OAG: Open-angle glaucoma; OHT: Ocular hypertension; SBP: Systolic blood 





Figure 1. Flow chart of study selection process for the meta-analysis of the association 






Figure 2. Relative risks for primary open-angle glaucoma comparing patients with to 
those without hypertension. 
 
The size of the box representing the point estimate for each study in the forest plot is 
proportional to the contributing weight of that study estimate to the summary estimate. 






Figure 3. Relative risk for primary open-angle glaucoma with increasing levels of blood 
pressures in dose-response meta-analysis. 
 
Circle areas are inversely proportional to the variance of the log relative risks from 
studies using categorical systolic blood pressure or diastolic blood pressure intervals. Dashed 
lines correspond to studies that used systolic blood pressure or diastolic blood pressure as a 
continuous variable. The pooled linear risk trend (thick solid line) and its 95% confidence band 
(shaded region) were obtained using a random-effects dose-response meta-analysis. The 
individual studies were: 1: Tan et al., 2009; 2: Kaimbo et al., 2001; 3: Memarzadeh et al., 2010; 
4: Tielsch et al., 1995; 5: Hulsman et al., 2007; 6: Katz et al., 1988; 7: Quigley et al., 2001; 8: 




 Figure 4. Increase in intraocular pressure associated with a 10 mm Hg increase in 
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7 Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. 
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8 Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto 
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9 Nomura H, Ando F, Niino N, Shimokata H, Miyake Y. The relationship between age and intraocular pressure in a Japanese population: the influence of 
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19 Wang S, Xu L, Jonas JB, et al. Major eye diseases and risk factors associated with systemic hypertension in an adult Chinese population: the Beijing Eye 
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24 Graw J, Welzl G, Ahmad N, et al. The KORA Eye Study: a population-based study on eye diseases in Southern Germany (KORA F4). Invest Ophthalmol 
Vis Sci. 2011;52(10):7778-7786. 
25 Ishikawa M, Sawada Y, Sato N, Yoshitomi T. Risk factors for primary open-angle glaucoma in Japanese subjects attending community health screenings. 
Clin Ophthalmol Auckl NZ. 2011;5:1531-1537. 
26 Topouzis F, Wilson MR, Harris A, et al. Risk factors for primary open-angle glaucoma and pseudoexfoliative glaucoma in the Thessaloniki eye study. Am J 
Ophthalmol. 2011;152(2):219-228.e1. 
27 Goldacre MJ, Wotton CJ, Keenan TDL. Risk of selected eye diseases in people admitted to hospital for hypertension or diabetes mellitus: record linkage 
studies. Br J Ophthalmol. 2012;96(6):872-876.  
28 Kim M, Kim T-W, Park KH, Kim JM. Risk factors for primary open-angle glaucoma in South Korea: the Namil study. Jpn J Ophthalmol. 2012;56(4):324-329. 
29 Lee MK, Cho S-I, Kim H, et al. Epidemiologic characteristics of intraocular pressure in the South Korean and Mongolian populations: the Healthy Twin and 
the GENDISCAN study. Ophthalmology. 2012;119(3):450-457.  
30 Sun J, Zhou X, Kang Y, et al. Prevalence and risk factors for primary open-angle glaucoma in a rural northeast China population: a population-based 
survey in Bin County, Harbin. Eye Lond Engl. 2012;26(2):283-291.  
Case-control 
1 Morgan RW, Drance SM. Chronic open-angle glaucoma and ocular hypertension. An epidemiological study. Br J Ophthalmol. 1975;59(4):211-215. 
2 Reynolds DC. Relative risk factors in chronic open-angle glaucoma: an epidemiological study. Am J Optom Physiol Opt. 1977;54(2):116-120. 
3 Wilson MR, Hertzmark E, Walker AM, Childs-Shaw K, Epstein DL. A case-control study of risk factors in open angle glaucoma. Arch Ophthalmol. 
1987;105(8):1066-1071. 
4 Katz J, Sommer A. Risk factors for primary open angle glaucoma. Am J Prev Med. 1988;4(2):110-114. 
5 Uhm KB, Shin DH. Glaucoma risk factors in primary open-angle glaucoma patients compared to ocular hypertensives and control subjects. Korean J 
Ophthalmol KJO. 1992;6(2):91-99. 
6 Charliat G, Jolly D, Blanchard F. Genetic risk factor in primary open-angle glaucoma: a case-control study. Ophthalmic Epidemiol. 1994;1(3):131-138. 
7 Kaimbo DK, Buntinx F, Missotten L. Risk factors for open-angle glaucoma: a case-control study. J Clin Epidemiol. 2001;54(2):166-171. 
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2 Hennis A, Wu S-Y, Nemesure B, Leske MC. Hypertension, diabetes, and longitudinal changes in intraocular pressure. Ophthalmology. 2003;110(5):908-
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3 Klein BEK, Klein R, Knudtson MD. Intraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J 
Ophthalmol. 2005;89(3):284-287.  
4 Nakano T, Tatemichi M, Miura Y, Sugita M, Kitahara K. Long-term physiologic changes of intraocular pressure: a 10-year longitudinal analysis in young and 
middle-aged Japanese men. Ophthalmology. 2005;112(4):609-616.  
5 Wu S-Y, Nemesure B, Hennis A, Leske MC. Nine-year changes in intraocular pressure: the Barbados Eye Studies. Arch Ophthalmol. 2006;124(11):1631-
1636. 
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Supplemental Table  2. Hypertension ascertainment method in studies included in meta-analysis of the association between blood 
pressure and primary open-angle glaucoma. 
First author, year SBP, mm Hg DBP, mm Hg Medication Self-report history Medical 
record 
Morgan, 1975 - - Y - - 
Reynolds, 1977 Age<44:>140 Age<44:>90 - - - 
Age 45-64:>150 Age 45-64:>95 
Age≥65: >160 Age≥65: >95 
Wilson, 1987 ≥160 - Y - - 
Katz, 1988 - - Y - - 
Uhm, 1992 - - - Y - 
Charliat, 1994 - - - Y - 
Dielemans, 1995 ≥160 ≥95 - - - 
Tielsch, 1995 ≥140 ≥90 Y - - 
Bonomi, 2000 >160 >95 Y - - 
kaimbo, 2001 ≥160 ≥95 Y Y - 
Quigley, 2001 ≥160 ≥90 Y - - 
Fan, 2004 - - - Y - 
Mitchell, 2004 ≥160 ≥95 Y Y - 
Bai, 2005 >160 >95 - Y - 
Orzalesi, 2007 - - - Y - 
Leske, 2008 ≥140 ≥90 Y - - 
Vijaya, 2008 ≥140 ≥90 Y - - 
Tan, 2009 ≥130 ≥85 Y - - 
Wang, 2009 ≥140 ≥90 Y - - 
Graw, 2011 ≥140 ≥90 Y Y - 
Ishikawa, 2011 ≥140 ≥90 - - - 
Newman-Casey, 2011 - - - - Y 
Topouzis, 2011 ≥140 ≥90 - - - 
Goldacre, 2012 - - - - Y 
Kim, 2012 - - - Y - 
Sun, 2012 ≥140 ≥90 Y - - 










Leske, 1983 Age, sex 
David, 1987 Age 
Wormald, 1994 Age, sex, diabetes, skin color, place of birth 
Dielemans, 
1995 
Age, sex, BMI 
Tielsch, 1995 Age, race 
Nomura, 1999 Age, BMI, DBP, SBP 
Bonomi, 2000 Age, sex 
Quigley, 2001 Age 
Nomura, 2002 Age, CCT, BMI, sex 
Yoshida, 2003 Age, BMI, SBP, alcohol, smoking, exercise , coffee 
Mitchell, 2004 Age, sex, maximum IOP, glaucoma family history, myopia, current thyroxine use, pseudoexfoliation, and diabetes 
Bai, 2005 Age, sex 
Chen, 2005 Age, glucose, triglyceride, sex 
Mitchell, 2005 Age, diabetes, smoking, myopia, iris color, glaucoma family history, pseudoexfoliation 
Oh, 2005 Age, sex, weight, height, BMI, waist circumference, body fat percent, blood pressure, LDL cholesterol, HDL cholesterol, log triglycerides, log fasting 
insulin, and/or the insulin sensitivity indices 
Hulsman, 2007 Age, sex, BMI, smoking, diabetes mellitus, serum cholesterol level, and BP-lowering treatment 
Vijaya, 2008 Age, sex, IOP, CCT, myopia 
Tan, 2009 Age, sex, education, smoking status, central corneal thickness, and diabetic treatment (none, diet, or oral/insulin) 
Wang, 2009 Age, sex, area of habitation, BMI, glucose, cholesterol, LDL, HDL, education, income 
Chang, 2010 Age, sex 
Imai, 2010 Age, maximum temperature, abdominal circumference, fasting glucose, HDL, triglyceride 
Memarzadeh, 
2010 
Age, IOP, history of glaucoma treatment, history of elevated BP and treatment of BP  
Park, 2010 Age, waist, triglyceride 
Graw, 2011 Age, sex 
Ishikawa, 2011 Age, sex, diastolic blood pressure, intraocular pressure, ocular perfusion pressure 
Topouzis, 2011 Age, IOP, diabetes, diabetes treatment, coronary artery bypass or vascular surgery, myopia 
Goldacre, 2012 ORLS: Age, sex, time-period, district of residence in the ORLS datasets 
LHES: Age, sex, time-period, region of residence and deprivation score associated with patients’ area of residence 
Kim, 2012 Age, diabetes, thyroid disease, family history of glaucoma, IOP 
Lee, 2012 Age, sex 
Sun, 2012 Age, family history of glaucoma, IOP 
Case-control  
Morgan, 1975 Age, sex, education, income 





Wilson, 1987 Age, sex, race, family history of POAG, SBP, smoking, myopia, radiation exposure, metal exposure, and reason for attendance at our general eye 
service 
Katz, 1988 Age, race and sex 
Uhm, 1992 Age, race, diabetes, family history of glaucoma 
Charliat, 1994 Age at time of diagnosis (±2 years), type of health care (public hospital vs. private practice), sex  
kaimbo, 2001 Age, gender, Mongo, Born place, Diet habbit (rice vs others), family history of glaucoma, diabetes, alcohol, smoking, hyperopia, cataract, BMI 
Fan, 2004 Age, sex, family history of glaucoma, cigarette smoking, alcohol consumption, myocilin sequence alteration T353i 
Orzalesi, 2007 Age 
Longitudinal   
Mcleod, 1990 Baseline age, baseline IOP, baseline BP 
Hennis, 2003 Age, baseline IOP, diabetes history, 
Klein, 2005 Age, sex, baseline IOP, BP medication, diabetes 
Nakano, 2005 Age and gender 
Wu, 2006 Age, sex, and baseline IOP 
Leske, 2008 Age, gender, IOP, and IOP- and blood pressure–lowering treatment 
Newman-
Casey, 2011 
Age, sex, race, education level, house-hold net worth, region of residence at the time of medical plan enrollment, cataract, pseudophakia or aphakia, 
macular degeneration, diabetic retinopathy, hypotension, sleep apnea syndrome, migraine headache, Charlson comorbidity index, and each of the 
other metabolic syndrome 
*BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; CCT: Central corneal thickness; IOP: Intraocular pressure; LDL: Low density 
lipoprotein; HDL: High density lipoprotein; POAG: Primary open-angle glaucoma; BP: Blood pressure; ORLS: Oxford Record Linkage Study; LHES: English linked 

































































































NA 3317  NA 21-60  SBP: 0.03 
(p<0.05) 
Age, heart rate, weight 









GAT SBP 1994 3654 16 ≥49  0.213 (p<0.001) Age, family history of 
glaucoma, diabetes, 
myopia 
Lin, 2005 Taiwan Randomly sampled Commu
nity 








2000 2597 Left: 
14.5 
57.0  0.121 
(p<0.0001) 
Age, BMI, SBP, DBP, 
a history of diabetes, a 
history of smoking, 





Lee, 2008 South 
Korea 










 Male: 0.151 
(p<0.001) 
Age, triglyceride, HDL, 
















Malay Eye Study 
Commu
nity 
GAT SBP 2006 3280 NA 40-80  0.033 (p<0.001) Age, SBP, CCT, sex, 
spherical equivalent, 
diabetes, and smoking 
Tomoyose, 
2010 




GAT  SBP, 
DBP 




Age, gender, BMI, 
corneal curvature, 
axial length DBP: 0.19 
(P< .001) 




NCT  HTN 2004 1348 15.2 65.1  0.82 (p<0.001) Age, gender, BMI, 
CCT 
Suh, 2012 South 
Korea 
The Namil Study Commu
nity 
GAT  HTN 2008 3191 14.1 58.7 0.62   0.408 (p<0.05) Age, sex, area, CCT, 
Refractive error, cup 
to disc ratio, family 









NCT HTN 2008 4335 14.0 54.7  Men: 0.370 
(p=0.001) 






*GAT: Goldmann Applanation Tonometer; ST: Schiotz tonometer; PAT: Perkins applanation tonometer; NCT: Non-contact tonometer; BMI: Body mass index; SBP: 
Systolic blood pressure; DBP: Diastolic blood pressure; CCT: Central corneal thickness; IOP: Intraocular pressure; LDL: Low density lipoprotein; HDL: High density 









Supplemental Figure 1. Funnel plots for the meta-analyses of systolic and diastolic blood pressure with intraocular pressure and 
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Topic: We performed a meta-analysis to summarize the association of diabetes and blood 
glucose levels with glaucoma, intraocular pressure (IOP) and ocular hypertension in the general 
population. 
Clinical relevance: Diabetes has been proposed as a risk factor for glaucoma, but 
epidemiological studies have been inconsistent and the association is still controversial. Cohort 
studies have never been appraised systematically. Furthermore, there are no systematic reviews 
evaluating other metabolic abnormalities, such as the metabolic syndrome, with the risk of 
glaucoma. 
Methods: Studies were identified by searching the PubMed and EMBASE databases. Inverse-
variance weighted random-effects models were used to summarize relative risks across studies.  
Results: We identified 47 studies including 2,981,342 individuals from 16 countries. The 
pooled RR for glaucoma comparing patients with to those without diabetes was 1.48 (95% CI 
1.29 – 1.71), with significant heterogeneity across studies (I2 82.3%, p < 0.001). The risk of 
glaucoma increased by 5% (95% CI 1 – 9%) for each year since diabetes diagnosis. The pooled 
average difference in IOP comparing patients with to those without diabetes was 0.18 mm Hg 
(95% CI 0.09 – 0.27, I2 73.2%), while the pooled average increase in IOP associated with an 
increase in 10 mg/dL in fasting glucose was 0.09 mm Hg (95% CI 0.05 – 0.12, I2 34.8%). 
Limited data on the association between HbA1c and metabolic syndrome with glaucoma 
precluded the calculation of pooled estimates.  
Conclusions: Diabetes, diabetes duration, and fasting glucose levels were associated with a 
significantly increased risk of glaucoma, and diabetes and fasting glucose levels were 






Glaucoma, the most common cause of irreversible blindness worldwide, represents a 
major public health problem 1. The number of glaucoma patients in the US is expected to 
increase from 2.7 million in 2010 to 6.3 million in 2050 2. Elevated intraocular pressure (IOP) 
or ocular hypertension (OHT) is the only well-established modifiable risk factor for primary 
open-angle glaucoma (POAG), the most common form of glaucoma. There is thus considerable 
interest in identifying potentially modifiable risk factors for glaucoma in order to develop 
interventions that may reduce the incidence or improve the prognosis of the disease. 
Diabetes mellitus has been suggested to causes microvascular damage and vascular 
dysregulation of the retina and the optic disc, increasing the susceptibility of the optic nerve 
head to damage in glaucoma 3–5.  Diabetes may also result in elevated IOP and increased risk of 
POAG by disrupting the trabecular meshwork function 6. Diabetes has been proposed as a risk 
factor for elevated IOP and POAG, but epidemiological studies of the association between 
diabetes mellitus and glaucoma have been inconsistent 7–10 and the association is still 
controversial.  
A meta-analysis published in 2004 evaluated the available literature on the association 
between diabetes mellitus and glaucoma 11. This meta-analysis was based on 12 cross-sectional 
or case-control studies published before 2002. Several studies, including 6 longitudinal studies 
published in the past 10 years, have never been appraised systematically. Furthermore, there are 
no systematic reviews evaluating other metabolic abnormalities, such as the metabolic 
syndrome, with the risk of glaucoma. Our objective was thus to conduct a comprehensive and 





diabetes duration, metabolic syndrome, and glucose levels with the risk of glaucoma and with 
IOP levels in the general population. 
METHODS 
Search Strategy and Study Selection 
Our systematic review and meta-analysis was conducted according to the Meta-analysis 
of Observational Studies in Epidemiology (MOOSE) guidelines 12. The protocol for the 
systematic review was registered in the International Database of Prospectively Registered 
Systematic Reviews (PROSPERO number CRD42013005989). We searched MEDLINE and 
EMBASE to identify relevant studies. The search items were based on established terminology 
using MESH and EMBASE extensive search terms when possible. Keywords included diabetes 
mellitus, diabetes, metabolic syndrome, hyperglycemia, insulin resistance, hyperinsulinism, 
blood glucose, hemoglobin A1c, blood sugar, pancreas islet disease, intraocular pressure, 
intraocular tension, eye pressure, eye internal pressure, intraorbital pressure, ocular pressure, 
ocular tension, intraocular hypertension, intraocular tension, and glaucoma. The terms 
“diabetes” and “glaucoma” are general key terms that cover their subtypes in MEDLINE and 
EMBASE database searches.  We also manually reviewed the reference lists from retrieved 
articles and identified additional relevant studies. The databases were searched for reports 
published through May 2013 with no language restrictions. 
We aimed to identify all studies reporting an association between diabetes, metabolic 
syndrome, or glucose levels with glaucoma, IOP levels, or OHT in adults 18 years of age or 
older. The exclusion criteria were: (a) no original research (reviews, commentaries, editorials, 





studies conducted in population samples comprised only of patients with diabetes, metabolic 
syndrome, glaucoma or OHT at baseline; (e) studies not reporting glaucoma, IOP or OHT as 
outcomes; (f) studies not using diabetes, metabolic syndrome, blood glucose, or HbA1c as 
exposures; (g) studies mainly investigating drug effects or metabolism; (h) studies conducted in 
population samples comprised only of patients with specific conditions (e.g., hemodialysis, eye 
surgery) that limit their generalizability to general population samples. Since age is a strong 
risk factor for glaucoma and for diabetes development, we further excluded studies that did not 
adjust for age in the design or the analysis.  
The study endpoints were POAG, IOP, and OHT. For studies that did not report POAG 
separately from other types of glaucoma, we used results for open angle glaucoma or glaucoma 
as endpoints. If more than one published paper reported on the same association within a study 
population, we selected the most recent publication or the publication with the longest follow-
up. Studies reporting only correlation coefficients or point estimates of other measures of 
association without standard errors or any other estimates of statistical variability were included 
in the systematic review, but were excluded from the quantitative meta-analysis. 
Data Extraction and Quality Assessment 
Two authors (D.Z. and M.K.) independently reviewed all search results to identify 
eligible studies and abstracted data from selected articles. Discrepancies between reviewers 
were resolved by consensus or adjudication by the 3rd reviewer (E.G.). The following data 
were extracted from each study: publication year, country where the study was performed, 
study period, study size, sex and age of study participants, measure and range of exposure, 
methods for identification of type 2 diabetes, variables adjusted for in the analysis, and reported 





quality using the methods described by Sanderson et al 13 and Viswanathan et al 14. We 
examined the methods for selecting study participants, the criteria for defining exposures and 
outcomes, the risk of bias associated with different designs, the methods used to control for 
confounding, and potential conflicts of interest. 
Statistical Analysis 
We conducted separate meta-analysis for each combination of exposure (diabetes, 
diabetes duration, metabolic syndrome, and glucose levels) and outcome (glaucoma, IOP, and 
OHT) using random-effects meta-analyses to combine study-specific measures of association. 
For binary outcomes (glaucoma and OHT), the measures of association abstracted (odds ratios, 
incidence risk ratios, and hazard ratios) were combined together and referred to as relative risk 
(RR). We estimated the pooled average difference in IOP in mmHg comparing patients with 
and without diabetes and comparing patients with and without metabolic syndrome, as well as 
the pooled average difference in IOP associated with an increase in 10 mg/dL of serum glucose. 
Finally, we estimated the increase in glaucoma risk associated with a 1-year increase in 
diabetes duration compared to no diabetes by using a random-effects dose-response meta-
analysis 15,16.  
When a study reported several models for a given end point, we used the measure of 
association with the greatest degree of control for potential confounders. For studies reporting 
results separately by subgroup (e.g., men and women, diabetes with treatment and without 
treatment), we used the result for each group as independent results for the meta-analysis. For 
studies reporting standardized regression coefficients, we used the standard deviations reported 





Between-study heterogeneity was quantified using the I2 statistic. We also conducted 
sensitivity analyses omitting one study at a time to assess whether results were markedly 
affected by any single study. Publication bias was evaluated by funnel plots and by Egger's 
tests 17. To examine potential sources of heterogeneity by study type (case-control, cross-
sectional, longitudinal), location (Europe, America, Asia, other), year of publication (<2000, 
≥2000), and exposure and outcome definitions we used meta-regression models with restricted 
maximum likelihood estimation of between-study variance. Meta-analyses were conducted 
with Stata version 12 (STATA Corp, College Station, TX). 
RESULTS 
We identified 47 studies including 2,981,342 individuals from 16 countries 
(Supplementary Figure 1; Supplementary Table 1). Sixteen studies were performed in North 
America, 15 in Asia, 11 in Europe, 2 in Australia, 1 in Africa, 1 in the Middle East, and 1 in the 
West Indies (Table 1). Thirty-two studies were cross-sectional, 9 were case-control, and 6 were 
longitudinal. Twenty-nine studies reported on the association between diabetes and glaucoma, 
5 on diabetes duration and glaucoma, 2 on HbA1c and glaucoma, 1 on metabolic syndrome, 
glucose levels and glaucoma, 11 on diabetes and IOP levels, 6 on glucose and IOP levels, 6 on 
diabetes and OHT, and 1 on glucose and OHT. The definitions of the exposures and outcomes, 
and factors used for adjustment in each study are summarized in Supplementary Tables 2 and 
3.   
The prevalence of glaucoma ranged from 1.5 to 8.1%, and the prevalence of OHT 
ranged from 1.1 to 10.9% across studies. Among 29 studies that used glaucoma as outcome, 10 
studies used characteristics of the optic disc, anterior chamber angle, optic nerve damage or 





criteria, 4 studies used medical records, medication prescription records or medical database 
data, and 5 studies used self-reports. Among 17 studies using IOP levels as outcome, 7 
measured IOP using Goldmann applanation tonometers and 10 measured IOP using non-
contact tonometers.  
 
Glaucoma 
The pooled RR for glaucoma comparing patients with to those without diabetes was 
1.48 (95% CI 1.29 – 1.71), with significant heterogeneity across studies (I2 82.3%, p < 0.001) 
(Figure 1). The estimates from cross-sectional, case-control, and longitudinal studies were 
similar (RRs of 1.58, 1.44, and 1.37, respectively). The results were also similar by country, 
method for ascertainment of diabetes, criteria for defining glaucoma, and year of publication. 
However, the pooled RR for studies using exclusively POAG as outcome was 1.23 (95% CI 
1.04 – 1.45), while the RR for studies using open angle glaucoma or glaucoma as outcome was 
1.71 (95% CI 1.44 – 2.03). The pooled RRs obtained after omitting 1 study at a time ranged 
from 1.43 to 1.52. Egger's test for publication bias was statistically significant (p < 0.001) and 
funnel plots suggested that small studies were reporting stronger associations compared with 
larger studies, although large studies also reported positive associations.  
Among five studies with dose-response data on the association of diabetes duration with 
glaucoma, the risk of glaucoma increased by 5% (95% CI 1 – 9%) for each year since diabetes 
diagnosis (Figure 2). In one study reporting the association between metabolic syndrome and 
POAG 22, the RR for POAG comparing participants with ≥2 metabolic syndrome components 





reported the association between impaired blood glucose and POAG 31 with a RR of 1.2 (95% 
CI 0.8 – 1.8). 
 
Intraocular pressure 
The pooled average difference in IOP comparing patients with to those without diabetes 
was 0.18 mm Hg (95% CI 0.09 – 0.27), with substantial heterogeneity (I2 72.3%) (Figure 3). 
The pooled estimates were not statistically different by study design, country, method for 
ascertainment of diabetes, method of IOP measurement, and year of publication (<2000, 
≥2000). The pooled average differences in IOP comparing participants with to those without 
diabetes obtained after omitting one study at a time ranged from 0.14 to 0.34 mm Hg. Although 
Egger's test for publication bias was not significant, funnel plots suggested that small studies 
were reporting stronger associations compared with larger studies.  Two additional studies 
reported regression coefficients without measures of variability and could not be incorporated 
in the pooled analysis. A study in Taiwan reported higher IOP levels among participants with 
diabetes compared to those without diabetes (regression coefficient 0.12 mm Hg, p < 0.001) 
while a study in Turkey reported lower IOP levels among participants with diabetes compared 
to those without diabetes (regression coefficient -0.13, p < 0.001) 32,33. 
The pooled average increase in IOP associated with an increase in 10 mg/dL in fasting 
glucose was 0.09 mm Hg (95% CI 0.05 – 0.12, I2 34.8%) (Supplemental Figure 2).  The 
estimates ranged from 0.08 to 0.09 mm Hg after omitting one study at a time. Egger's test for 
publication bias was significant (p = 0.01) with small studies reporting stronger associations 







One case-control study, 4 cross-sectional studies and 1 longitudinal study reported data 
on the association between diabetes and OHT (Supplemental Figure 3). The pooled RR for 
OHT comparing participants with to those without diabetes was 1.52 (95% CI 1.11 – 2.09, I2 
53.1%). RR estimates were lower in case-control compared with cross-sectional studies or 
longitudinal studies (0.14, 1.69, and 1.38, respectively), but the results did not vary by year of 
publication, country, IOP threshold to determine OHT, or diabetes definition criteria. After 
omitting one study at a time, the pooled RRs varied from 1.37 to 1.62.  Finally, one study 
reported data on the association between impaired fasting glucose (defined as ≥100 mg/dL) and 
OHT (RR 2.12, 95% CI 1.30 – 3.45) 34.  
DISCUSSION 
In this comprehensive meta-analysis, diabetes was associated with a significantly 
increased risk of glaucoma and with increased levels of IOP and OHT.  Importantly, the 
association was also evident in longitudinal studies, which are less subject to bias than cross-
sectional or case-control studies. We also identified positive associations between diabetes 
duration and the risk of glaucoma, and a weak association between fasting glucose levels and 
increased IOP levels. Finally, we identified a relative lack of research on the association 
between glucose biomarkers, prediabetes and metabolic syndrome with glaucoma. Given the 
high prevalence of these metabolic abnormalities, future studies should target this area of 
research to fully understand the implications of altered glucose metabolism on glaucoma risk. 
The mechanisms relating diabetes to increased IOP are unclear. Increased IOP in 
diabetes may be due to hyperglycemia, which may induce an osmotic gradient that draws 





Hyperglycemia may also increase IOP by interrupting the trabecular meshwork function 6. In 
addition, diabetes may increase corneal stiffness and central corneal thickness, which may 
artificially raise IOP readings 36–38. The association between diabetes and IOP, however, was 
weak suggesting that the association between of diabetes and glaucoma may in part be 
independent of raised IOP. This is also supported by the fact that the association between 
diabetes and glaucoma in our meta-analysis was similar in studies that used IOP as criteria for 
defining glaucoma compared to those that did not use IOP.   
Vascular mechanisms have been implicated to explain the increased risk of glaucoma in 
patients with diabetes irrespective of IOP levels. Diabetes causes microvascular damage and 
may affect vascular autoregulation of the retina and optic nerve 3,31,39. Vascular damage can 
reduce blood flow and impair oxygen diffusion. Endothelial cell injury and dysfunction can 
reduce the autoregulatory capacity to protect against fluctuations of IOP and blood pressure 40–
43, which could lead to relative hypoxia and to damage of the optic nerve head and of the retinal 
nerve fiber layer 38. Furthermore, vascular changes in diabetes may increase the susceptibility 
of the retina to additional stress related to POAG or IOP elevation 5. In addition to vascular 
changes, diabetes impairs physiological glial and neuronal function in the retina, which may 
increase the susceptibility of retinal ganglion cells to glaucomatous damage 4.  
We also found that longer duration of diabetes was associated with higher risk of 
glaucoma. This robust association was consistent across cross-sectional, case-control and 
longitudinal studies and was independent of age, race, sex and other confounders controlled in 
the original studies.  A longer duration of diabetes could impose prolonged damage to the glial 





for patients with longer duration of diabetes to adhere to optimal glaucoma screening exams 
and management.  
As diabetes is a known risk factor for a variety of ocular diseases besides glaucoma, 
patients with diabetes are more likely to receive eye examinations. This may result in an 
overestimation of the association between diabetes and glaucoma, as the higher prevalence of 
glaucoma in patients with diabetes may be a reflection of more frequent ophthalmologic visits. 
In addition, it’s also possible that retinal disease from diabetic retinopathy could lead to visual 
field defects, and could result in over-diagnosis of glaucoma in these studies.  Indeed, the 
Beaver Dam Eye Study reported that the proportion of participants who had seen an 
ophthalmologist in the 2 years before enrollment was significantly higher in patients with 
diabetes compared to those without it 44. Similarly, 22% of incident cases of glaucoma or OHT 
detected in diabetic patients in a retrospective cohort study were attributable to contact with 
medical services for diabetes screening 10. However, other studies suggest that selection or 
information biases were unlikely to explain the association between diabetes and glaucoma. In 
the Nurses’ Health Study, a longitudinal cohort study, participants with diabetes reported the 
same number of eye examinations on serial occasions as those without diabetes, and the 
prospective association between diabetes and glaucoma was unchanged when adjusting for 
factors that predicted more thorough eye examinations 45. Also, in the Blue Mountains Eye 
Study, most of previously diagnosed cases of glaucoma had been diagnosed before the 
diagnosis of diabetes 7, indicating that the positive association between diabetes and risk of 
glaucoma cannot be completely explained by surveillance bias.  
Several limitations need to be considered in the interpretation of our findings. First, 





methods used to ascertain exposure and outcomes varied widely across studies, likely 
contributing to the high degree of heterogeneity in the results. For instance, in our meta-
regression analysis, studies using non-contact tonometers showed stronger associations 
between diabetes and IOP compared with studies using Goldmann applanation tonometers, the 
gold standard for measuring IOP. Second, there was also heterogeneity in the covariates 
adjusted for in each study. We attempted to limit the influence of uncontrolled confounders on 
this meta-analysis by excluding studies that did not adjust for age. However, some studies may 
still be affected by uncontrolled or residual confounding by factors such as ethnicity or central 
corneal thickness (CCT). For example, we found that studies that adjusted for CCT showed 
stronger associations between diabetes and IOP compared with studies that did not adjust for 
CCT (P <0.001). Reassuringly, the findings of the meta-analysis were consistent in early 
studies, which tended to show more methodological limitations, and in more recent studies. 
Similarly, sensitivity analyses found that the results were consistent across study designs, 
location, and exposure and outcome assessment and definitions. This consistency adds weight 
to the internal validity of our findings.  
Another concern was the lack of evidence of the effect modification by types of 
diabetes. The association between diabetes and the glaucomatous process may be different in 
type 1 diabetes, in which lack of insulin production leads to increased blood glucose, compared 
with type 2 diabetes, in which insulin resistance is the primary underlying mechanism. 
However, detailed information on the type of diabetes was not available in the original studies. 
In our meta-analysis, we found that patients with diabetes treated with insulin had a higher risk 





identify if insulin was used in the context of type 1 or type 2 diabetes. Future studies should 
characterize the implications of the different types of diabetes on glaucoma risk. 
Strengths of this meta-analysis included the large sample of studies combined, the 
evaluation of multiple diabetes-related exposures and glaucoma-related outcomes, and the 
inclusion of prospective studies, which provide natural estimates of incidence and temporal 
trends and can establish the temporal sequence required for causal inference. 
In conclusion, we found that diabetes, diabetes duration, and fasting glucose levels were 
associated with a significantly increased risk of POAG, and that diabetes and fasting glucose 
levels were associated with increased levels of IOP.  As a consequence, the importance of 
glaucoma screening in patients with diabetes, particularly those with long-standing disease, 
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Figure 1. Relative risk for glaucoma comparing patients with to those without diabetes. 
 
The size of the box representing the point estimate for each study in the forest plot is 
proportional to the contributing weight of that study estimate to the summary estimate. 







Figure 2. Relative risk for glaucoma with increasing duration of diabetes in dose-
response meta-analysis. 
 
Circle areas are inversely proportional to the variance of the log relative risks. The 
pooled linear risk trend (thick solid line) and its 95% confidence band (shaded region) were 
obtained using a random-effects dose-response meta-analysis. The individual studies were: 1: 
Pasquale et al., 2006; 2: Wise et al., 2011; 3: Welinder et al., 2009; 4: Chopra et al., 2008; 5: 






Figure 3. Difference in intraocular pressure comparing patients with to those without 
diabetes. 
 
The size of the box representing the point estimate for each study in the forest plot is 
proportional to the contributing weight of that study estimate to the summary estimate. 
























Cross-sectional         
Leske, 
1983 
US Framingham Heart Study and Framingham Eye 
Study 
Community 2,433 1975 NA NA NA NA 
David, 
1987 
Israel Asian, African, American or European origin Health 
screening exam 
2,594 1984 40-79 43.9 15.0 NA 
Krieger, 
1988 
US American Indians Community 560 NA 12-89 66.4 NA NA 
Klein, 
1994 
US Beaver Dam Eye Study Community 4,926 1990 43-84 55.2 NA 2.2 
Wormal
d, 1994 
UK African Caribbean subjects living in London Community 873 1991 >35 64.1 NA 3.5 
Tielsch, 
1995 
US Baltimore Eye Survey Community 5,308 1985-1988 ≥40 60.3 NA 3.0 
Mitchell, 
1997 
Australia Blue Mountains Eye study Community 3,654 1993 ≥49 NA NA 5.5 
Quigley, 
2001 
US Survey of Hispanics in Arizona Community 4,774 1990 >40 61.2 Healthy: 15.6  NA 
Rochtchi
na, 2002 
Australia Population-based survey Community 3,654 1992-1994 ≥49 56.6 DM: 16.5 








Taiwan Hospital based healthy subjects Health 
screening exam 
1,271 2001-2002 50.0 NA 13.6±2.9 NA 
Lin, 2005 Taiwan The Shihpai Eye Study Community 1,292 1999-2000 ≥65 40.0 12.9±3.1 NA 
Oh, 2005 South 
Korea 
Healthy visitors to health promotion center Health 
screening exam 
943 2003 Male: 15.7 
Female: 15.1 






Canada National survey Community 146,365 1994-95, 1996-
97 and 1998-99 
>20 NA NA Age ≥40: 2.7 
Age ≥50: 3.9 
Age ≥60: 5.6 
Age ≥70: 7.7 
Age ≥80: 11.0 
Chopra, 
2008 
US Los Angeles Latino Eye study Community 5,894 2000-2003 54.9 58 NA 4.9 
Kawase, 
2008 
Japan Taijimi study Community 2,597 2000 57.0 55.6 14.5 NA 
Tan, 
2009 
Singapore Singapore Malay Eye Study Community 3,280 2004-2006 58.7 51.9 NA 3.2 
Yazici, 
2009 
Turkey Subjects admitted to clinics Hospital 
outpatient 
clinic 
850 2006 Male: 43.9 
Female: 40.7 













1,044 2006- 2008 MS: 55.2 













14,003 2004-2008 14.8 41.5 NA NA 
Tomoyos
e, 2010 
Japan Kumejima Study Community 2,838 2005 58.4 48.9 15.1 NA 
Graw, 
2011 
Germany KORA Eye Study Community 2,593 1999 32-71 53.0 NA 1.5 
Ishikawa
, 2011 




710 2007 >30 46.0 POAG: 17.2 




Greece Thessaloniki Eye study Community 1,840 1999 POAG: 72.7 
No POAG: 
70.3 
45.0 POAG: 72.7 




China Liwan Eye Study Community 1,348 2003-2004 65. 57.3 15.2 NA 
Goldacre
, 2012 
UK Oxford Record Linkage Study (ORLS) and UK 













Local residents  Community 55 cases, 
1,409 
controls 
2008 Case: 68.4 
Control: 63.5 
NA Case: 15.7 
Control: 13.4 
NA 




10,491 2008 Male: 49.2 
Female: 50 







Namil Study Community 3,191 2005-2008 58.7 60.2 14.1 NA 
Zhou, 
2012 
China Handan Eye Study Community 6,101 2006-2007 >30 53.0 15.0 NA 
Chiang, 
2013 
Singapore Singapore Malay Eye Study Community 3,176 2004-2006 58.8 52.0 NA NA 
Hoehn, 
2013 
Germany Gutenberg Heath Study Community 4,335 2007-2008 54.7 48.9 14.0 NA 
Case-control         
Morgan, 
1975 
Canada Cases drawn from University of British 






NA NA NA NA NA 
Reynolds
, 1977 







1976 NA NA NA NA 
Wilson, 
1987 
US General Eye Service of the Massachusetts Eye 







1982-1984 NA 56.0 NA NA 
Katz, 
1988 
US Wilmer Institute, Johns Hopkins Hospital Hospital 
outpatient 














1993-1994 Case: 68.5 
Control: 62.8 







Patients attending a hospital for diagnosis and 







NA Cases: 62.9 
Controls: 
63.1 
NA NA NA 
Kaimbo, 
2001 






1997 Case: 28–80 
Control: 31–
81 











NA Case: 68 
Control: 65 





Denmark Danish National Registry of Patients (cases) 





2001-2006 median age 
70.4 
58.4 NA NA 
Longitudinal     
Ellis, 
2000 









NA NA Incidence in DM: 11 
per 10,000 person-
years  
Incidence in non-DM: 




US Nurses’ Health Study  Work cohort 43732 1980-2000 DM:  61 
No DM: 56 
100 NA Incidence 4.3 per 






Rotterdam Study Community 3837 Baseline 1990-
1993,  follow-
up 1997-1999 














US InVision Data Mart database Community 2182315 2001-2007 54.5 57.0 NA 2.5 
Wise, 
2011 
US Black Women’s Health Study Community 32570 1995-2007 21-69 100 NA Incidence 8.8 per 
10,000 person-years  
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Exposure  Exposure definition/measurement Outco
me 
Outcome definition/measurement 
Cross-sectional    
Leske, 
1983 
DM NA OHT OHT: IOP > 21 mm Hg without symptoms of POAG 
IOP: Goldmann applanation tonometer 
David, 
1987 
DM Self-report OHT OHT: IOP≥21 mm Hg without symptoms of POAG 





Diabetes Self-report; blood sugar randomly drawn IOP Goldmann applanation tonometer 
Klein, 
1994 
DM History of Diabetes treated with insulin or oral 
hypoglycemia agents and/or diet or glycosylated 
hemoglobin level >2 SD above the mean of the relevant 
age-sex group and a casual blood sugar level >11.1 mmol/l 
Glauco
ma 
Glaucoma: Visual field defect, cup-to-disc ratio, IOP≥22, history of taking drops for or having 
surgery for glaucoma  
IOP: Goldmann applanation tonometer 
Wormal
d, 1994 
DM, FBG History of diabetes treatment including diet alone, tablets 
and insulin dependence or a random blood sugar tested on 
a glucose check device with BM sticks above 15 mmol. 
Glauco
ma 
Already diagnosed as glaucoma (confirmed at survey) and receiving treatment or newly 
diagnosed during the survey and confirmed on follow-up assessment at Moorfields Eye Hospital 
on agreement by two ophthalmologists. 
Tielsch, 
1995 
DM Self-report POAG Glaucomatous optic nerve damage and optic disc ratio 
Mitchell, 
1997 
DM Self-report or FBG ≥7.8 mmol/L Glauco
ma, 
OHT 
Glaucoma: questionnaire, optic disc cupping and rim thinning, and visual field defects. 




DM Self-report or HbA1c ≥7% OAG OAG: 1 of the following sets of findings in at least 1 eye and had to have an open angle by 
gonioscopy: (1) 1 eye with optic disc damage and a visual field in the same eye; (2) at least 1 
eye with a cup-disc ratio ≥99.5th percentile for the population; and (3) visual acuity was in the 
legal blindness category and IOP ≥99.5 percentile for the population.  












FBG (mg/dl) Blood drawn IOP Noncontact tonometer 
Lin, 
2005 
DM Self-report IOP Noncontact tonometer 
Oh, 
2005 













DM: history of treatment for DM, HbA1c ≥7.0%, random 
blood glucose ≥200 mg/dL. 
Impaired glucose: random blood glucose ≥200 mg/dL. 
Impaired HbA1c: HbA1c ≥7.0%. 
OAG OAG: Open angle and a glaucomatous visual field abnormality and/or evidence of glaucomatous 
















DM: physician diagnosis of DM and use of diabetes 
medications or non-FBG ≥200 mg/dL or. Metabolic 
syndrome: at components were defined as follows: for 
obesity, BMI of 25 or greater; for hypertriglyceridemia, 
triglyceride level of 1504 mg/dL or greater; for low level 
of highdensity lipoprotein cholesterol, a value less than 
38.7 mg/dL in men and less than 50.3 mg/dL in women; 
for high blood pressure, 130/85 mm Hg or greater or use of 
blood pressure medication; and for Diabetes mellitus, as 
defined earlier 
POAG Glaucoma: IOP >21 mm Hg, gonioscopic findings of closed or occludable angles, presence of 
peripheral anterior synechiae, cup-disc ratio >0.6, disc asymmetry with cup-disc ratio >0.2, 
abnormal deposits on pupil margin consistent with pseudoexfoliation syndrome, pigment 
deposition on the cornea consistent with pigment dispersion syndrome, and known glaucoma. 
POAG: glaucoma without any evidence of narrow angles, primary angle-closure glaucoma, or a 
secondary cause (eg, abnormal anterior segment deposits or iris neovascularization). 
IOP: Goldmann applanation tonometer. 
Yazici, 
2009 
DM, FBG Self-report IOP Non-contact pneumotonometer 
Chang, 
2010 





FBG≥5.56 mmol/l OHT OHT: IOP>21 mm Hg without optic-disc abnormalities or history of receiving anti-glaucoma 
therapy 
IOP: non-contact tonometer 
Tomoyo
se, 2010 








DM HbA1c≥5.8% and/or previous diagnosis of DM POAG POAG: optic disk appearance, including cup-to-disk ratio, rim width, nerve fiber layer defect, 
the visual field test, and clinical records  
Topouzi
s, 2011 
DM Self-report POAG Glaucoma: Presence of thinning or notching or cup-to-disc ratio asymmetry of 0.2, and a 
confirmed threshold glaucomatous visual field defect, or a strong clinical judgment in favor of 
the presence of glaucoma  
POAG: glaucoma and an open, normal-appearing anterior chamber angle and the absence of 
other secondary causes of glaucoma in either eye.  
Wang, 
2011 
DM Self-report history or previous medication use IOP Handheld tonometer 
Goldacr
e, 2012 





DM Self-report POAG IOP levels, anterior chamber depth, gonioscopic results, appearance of the optic disc and retinal 







Postprandial blood sugar levels were also examined 
approximately 2 h after breakfast on the same day 
IOP Non-contact tonometer 
Suh, 
2012 
DM Self-report IOP Goldmann applanantion tonometer 
Zhou, 
2012 
DM Self-report IOP Perkins handheld applanation tonometer 





2013 duration a physician diagnosis OHT peripheral anterior synechiae, cup-disc ratio > 0.6, disc asymmetry with cup-disc ratio>0.2, 
abnormal deposits on pupil margin consistent with pseudoexfoliation syndrome, pigment 
deposition on the cornea consistent with pigment dispersion syndrome, and known glaucoma 
POAG: glaucoma without evidence of narrow angles, primary angle-closure glaucoma, or a 
secondary cause. 
OHT: IOP>21 mmHg 
IOP: Goldmann applanation tonometer 
Hoehn, 
2013 
DM Definite diagnosis and treatment, a blood glucose>126 
mg/dl after overnight fasting≥8 hours or a blood 
glucose >200 mg/dl after a fasting≥8 hours. 
IOP Noncontact tonometer 




DM NA POAG, 
OHT 
POAG: IOP > 21 mm Hg with optic disc change and field defect 













DM Self-report POAG POAG: IOP>21, glaucomatous visual field defects on at least two occasions 
IOP: Goldmann applanation tonometer 
Charliat
, 1994 
DM Self-report POAG Glaucomatous cupping in at least one eye 
Jonas, 
1998 
DM Antidiabetic diet, medication, or if blood sugar were above 
the normal range. 
POAG An open anterior chamber angle and glaucomatous changes of the optic nerve head and/or 
glaucomatous visual field defects.  
kaimbo, 
2001 
DM Self-report OAG OAG: IOP≥21 mm Hg, vertical cup/disc ratio, visual field defect. The diagnosis of OAG was 
based on at least two of the three criteria in at least one eye.  
IOP: Goldmann applanation tonometer 
Orzalesi, 
2007 
DM NA POAG Presence of a glaucomatous optic disc, or glaucomatous visual field changes, and open angle 





Prescription and hospital data. Glauco
ma 
Filling three or more prescriptions for a glaucoma medication over 365 days or less.  
Longitudinal    
Ellis, 
2000 
DM Diabetes Audit and Research in Tayside Study (DARTS) 
validated regional Diabetes register 
POAG, 
OHT 
Glaucoma: encashment of community prescriptions and the statutory surgical procedure coding 
database.   





Self-report POAG Gonioscopy was performed and that the angles were not occludable in either eye; slit-lamp 
biomicroscopy showed no indication in either eye of pigment dispersion syndrome, exfoliation 




DM Use of antidiabetic medication and/or a random or post 
load glucose value≥11.1 mmol/l 
OAG Presence of glaucomatous optic neuropathy and glaucomatous visual field loss, an open anterior 
chamber angle and no history or sign of angle-closure or secondary glaucoma. 
Wu, 
2006 








DM 1 or more of the following ICD-9 codes: 250.0, 250.00, 
250.01, 250.02, 250.03, 250.1, 250.10,250.11, 250.12, 
250.13, 250.2, 250.20, 250.21, 250.22, 250.23, 250.3, 
250.30,250.31, 250.32, 250.33, 250.4, 250.40, 250.41, 
250.42, 250.43, 250.5, 250.50,250.51, 250.52, 250.53, 
250.5, 250.50, 250.51, 250.52, 250.53, 250.6, 
250.60,250.61, 250.62, 250.63, 250.7, 250.70, 250.71, 
250.72, 250.73, 250.8, 250.80,250.81, 250.82, 250.83, 
250.9, 250.90, 250.91, 250.92, 250.93, 362.01, 362.92, 
362.03, 362.04, 362.05, 362.06, 362.07 





Self-report POAG Self-report 









Cross-sectional   
Leske, 1983 Age, sex, hypertension 
David, 1987 Age 
Krieger, 1988 Age, sex, weight index, BP, blood sugar, degree Indian 
Klein, 1994 Age, sex 
Wormald, 1994 Age, sex, hypertension, skin color, place of birth 
Tielsch, 1995 Age 
Mitchell, 1997 Age, gender 
Quigley, 2001 Age 
Rochtchina, 
2002 
Age, SBP, family history of Glaucoma,  myopia 
CDC, 2004 Demographic characteristics 
Chen, 2005 Age, SBP,DBP, tg, sex 
Lin, 2005 Age, SBP, sex, alcohol 
Oh, 2005 Age, sex, weight, height, BMI, waist circumference, body fat, BP, LDL, HDL, triglycerides, fasting insulin, and/or the insulin sensitivity 
indices 
Perruccio, 2007 Age, sex, income, education, and all chronic conditions  
Chopra, 2008 Age, gender, and IOP 
Kawase, 2008 Age, sex, BMI, SBP, DBP, smoking, CCT, the radius of corneal curvature, SE 
Tan, 2009 Age, sex, education, smoking, CCT and diabetic treatment  
Yazici, 2009 Age, sex, refractive status, CCT, hypertension, and hyperlipidemia 
Chang, 2010 Age, sex, DBP, triglycerides 
Imai, 2010 Age, temperature, abdominal circumference, BP, HDL cholesterol, triglyceride 
Tomoyose, 2010 Age, gender, BMI, corneal curvature, SBP, DBP, smoking, corneal curvature, CCT, anterior chamber depth, axial length, average Shaffer 
angle width grade 
Graw, 2011 Age, sex 
Ishikawa, 2011 Age, gender, DBP, IOP, and ocular perfusion pressure. 
Topouzis, 2011 Age, IOP, BP, Coronary artery bypass or vascular surgery, myopia 
Wang, 2011 Age, sex 
Goldacre, 2012 ORLS: Age, sex, time-period, district of residence in the ORLS datasets 
LHES: Age, sex, time-period, region of residence and deprivation score associated with patients’ area of residence 
Kim, 2012 Age, sex, hypertension, thyroid disease, family history of Glaucoma, IOP 
Lin, 2012 Age, sex, BMI, DBP, TG, hs_CRP 
Suh, 2012 Age, sex, area, CCT, RE, cup to disc ratio, family history of Glaucoma, CVD, smoking 
Zhou, 2012 Age, sex, smoking, mean arterial pressure, CCT, BMI, family history of Glaucoma, SE 
Chiang, 2013 Glaucoma: Age, gender 
OHT: Age, sex, income, HbA1c, hypertension, history of stroke and myocardial infarction, hyperlipidemia, BMI and smoking 
Hoehn, 2013 Age, iris color, CCT, waist-to-hip ratio, smoking, hypertension, dyslipidemia 
Case-control  
Morgan, 1975 Age, sex, education, income 
Reynolds, 1977 Age, sex and race 
Wilson, 1987 Age, sex, race, family history of POAG, sbp, smoking, myopia, radiation exposure, metal exposure, and reason for attendance 






BMI: body mass index; CCT: central corneal thickness; CVD: cardiovascular disease; DBP: diastolic blood pressure; DM: Diabetes Mellitus; FBG: Fasting blood glucose; MS: Metabolic syndrome; 
RE: refractive error; SES: social economic status; SE: spherical equivalent; SBP: systolic blood pressure. 
 
  
Charliat, 1994 Age, sex, type of health care 
Jonas, 1998 Age 
Kaimbo, 2001 Age, BMI, hyperopia, Mongo ethnic group, Rice 
Orzalesi, 2007 Age 
Welinder, 2009 Age, sex, and residence. CVD, hypertension,  thyroid disease, migraine,  autoimmune  disorders, alcoholism-related diagnoses, cataract, 
retinal detachment and uveitis 
Longitudinal  
Ellis, 2000 Age 
Pasquale, 2006 Age 
De Voogd, 2006 Age, gender, follow-up time, IOP, IOP–lowering treatment, BMI, systemic hypertension 
Wu, 2006 Age, sex, hypertension, and baseline IOP 
Newman-
Casey, 2011 
Age, sex, race, education level, house-hold net worth, region of residence at the time of medical plan enrollment, cataract, pseudophakia or 
aphakia, macular degeneration, diabetic retinopathy, hypotension, sleep apnea syndrome, migraine headache, Charlson comorbidity index, 
and each of the other metabolic syndrome 
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Background: Diabetes may affect vascular autoregulation of the retina and optic nerve and 
may be associated with an increased risk of glaucoma, but the association of prediabetes,  
insulin resistance,  markers of glucose metabolism with glaucoma has not been evaluated in 
general population samples. 
Objective: To examine the relation between diabetes, pre-diabetes, metabolic syndrome and its 
components and the levels of fasting glucose, HbA1c and HOMA-IR with the prevalence of 
glaucoma in the general U.S. population. 
Methods: Cross-sectional study of 3,299 adult men and women from the 2005 – 2008 National 
Health and Nutrition Examination Survey (NHANES).  The presence of diabetes, prediabetes, 
the metabolic syndrome and its individual components and biomarkers of glucose metabolisms 
were based on standardized questionnaire and physical exam data and laboratory tests. The 
history of glaucoma was assessed through questionnaire during the home interview. 
Results: Diabetes was strongly associated with prevalent glaucoma. In fully adjusted models, 
the odds ratio for glaucoma comparing participants with diabetes with participants in the 
reference group with neither pre-diabetes nor diabetes was 2.12 (95% CI: 1.23, 3.67).  The 
corresponding odd ratio comparing participants with pre-diabetes to those in the reference 
group was 1.01 (95% CI: 0.57, 1.82). Patients with 5 or more years of diabetes duration had an 
OR for glaucoma of 3.90 (95% CI: 1.63, 9.32) compared with patients with <5 years of 
diabetes duration. We also found a hockey-stick shaped associations between biomarkers of 





Conclusions: Diabetes was associated with higher risk of glaucoma. Participants without 
diabetes but at the higher levels of fasting glucose, fasting insulin, HbA1c and HOMA-IR 
spectrum may also be at greater risk of glaucoma.   
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Diabetes is a common chronic disease worldwide with a dramatic increase in incidence 
in recent decades 1. Diabetes is associated with a variety of ocular complications, including 
retinopathy, cataracts, uveitis and neovascularization 2. Several studies also suggested that 
diabetes may be associated with an increased risk of glaucoma 3–5. A meta-analysis of 12 
studies published prior to 2004 found a pooled odds ratio for primary open angle glaucoma 
(POAG) comparing participants with diabetes to those without diabetes of 1.50 (95% 
confidence interval [CI] 1.16 – 1.93) 6, but there was significant heterogeneity and many 
studies reported non-significant associations 7–11 or negative point estimates 12–15.  
Other abnormalities of glucose metabolism, including pre-diabetes, metabolic syndrome, 
insulin resistance, and elevated fasting glucose or hemoglobin A1c (HbA1c), may also be 
associated with glaucoma risk, but few studies have examined this issue, with conflicting 
results 16–19. The objective of this study was thus to examine the relation between diabetes, pre-
diabetes, metabolic syndrome, and markers of glucose metabolism with the prevalence of 
glaucoma in the U.S. population aged 40 years and older using data from the 2005–2008 
National Health and Nutrition Examination Survey (NHANES). 
RESEARCH DESIGN AND METHODS 
Study population 
The National Health and Nutrition Examination Survey (NHANES) is a nationally 
representative study of the non-institutionalized US population, obtained by using a stratified 
multistage probability design with planned oversampling of certain age and minority groups. 





Control and Prevention 20. Information on glaucoma prevalence was only available in the 2005 
– 2008 survey waves, and fasting glucose and insulin levels were only assessed in participants 
who were examined in the morning session. Therefore, we restricted our analysis to NHANES 
2005 – 2008 participants 40 years of age or older who were examined in the morning session 
(N = 3,299). We then excluded 255 participants whose duration of fasting was < 8 h (if they 
didn’t have a prior diagnosis of diabetes), 17 participants who had missing information 
regarding glaucoma in the questionnaire, and 1 participant with missing data in all exposure 
variables of interest. The final analysis was based on 3,026 participants (1,501 men and 1,525 
women). 
The 2005 – 2008 NHANES study protocols were approved by the Institutional Review 
Board of the National Center for Health Statistics. Written informed consent was obtained from 
all participants. 
Measurements 
NHANES included a standardized questionnaire administered at home by a trained 
interviewer and a detailed physical examination at a mobile examination center. Self-reported 
glaucoma status was ascertained via the question “Have you ever been told by an eye doctor 
that you have glaucoma, sometimes called high pressure in your eyes?” Demographic 
information, education, smoking history, physical activity levels, alcohol consumption, 
medication use, health history, and age of diabetes onset were also determined by self-report. 
Leisure-time physical activities were coded and classified according to the rate of energy 
expenditure (<7.5, 7.5 to <15, and ≥15 metabolic equivalent hours per week) to correspond 
with cut points in the 2008 US federal physical activity guidelines 21 and the 2010 World 





at the mobile examination center using standard procedures by trained health technicians 23,24. 
Body mass index (BMI) was calculated as weight in kilograms divided by height in meters 
squared.  
Fasting times ranged from 0.53 to 40.5 hours. Fasting blood samples were centrifuged 
and plasma was separated within 30 minutes from blood collection. Plasma glucose was 
analyzed using the hexokinase method in a Roche/Hitachi 911 (Roche Diagnostics, 9115 
Hague Road, Indianapolis, IN) and a Roche Modular P chemistry analyzer (Roche Diagnostics, 
9115 Hague Road, Indianapolis, IN) in 2005 – 2006 and 2007 – 2008, respectively 25. Fasting 
insulin was analyzed using Merocodia Insulin ELISA kits 20. HbA1c was measured using high-
performance liquid chromatography on an A1c 2.2 Plus Glycohemoglobin Analyzer (Tosoh 
Medics, Inc., San Francisco, Ca) in 2005 – 2006 and on an A1c G7 HPLC Glycohemoglobin 
Analyzer (Tosoh Medics, Inc., San Francisco, Ca) in 2007 – 2008 26. 
Diabetes was defined as a fasting plasma glucose level ≥ 126 mg/dL, an HbA1c level ≥ 
6.5%, a self-reported diagnosis of diabetes (excluding gestational diabetes mellitus), or a self-
report of current insulin or diabetes medication use. Pre-diabetes was defined in participants 
without diabetes as a fasting plasma glucose level between 100 mg/dL and 126 mg/dL, an 
HbA1c level between 5.7 and 6.5%, or a self-report of a diagnosis of borderline diabetes. 
Additional analyses were conducted defining diabetes and pre-diabetes using fasting plasma 
glucose or HbA1c criteria separately. Diabetes duration was calculated as the age at interview 
minus the age at the first time that the participant was told to have diabetes. 
Metabolic syndrome components were defined as detailed in the Adult Treatment Panel 
(ATP) III report 27:  1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women; 2) fasting 





4) blood pressure ≥ 130/85 mm Hg; and 5) fasting glucose ≥ 110 mg/dL or use of antidiabetic 
medication. Persons with at least 3 of these characteristics were defined as having metabolic 
syndrome. We also calculated the homeostatic model assessment of insulin resistance (HOMA-
IR) as fasting glucose (mg/dl) x fasting Insulin (uU/mL) / 405 and defined insulin resistance as 
HOMA-IR > 2.6 28. 
Statistical analysis 
All statistical analyses were performed using NHANES weights and svy commands in 
STATA (version 12; Stata Corp., College Station, TX) to account for the complex multistage 
probability sampling design. Analyses of fasting glucose, fasting insulin, HOMA-IR, and 
HbA1c levels were restricted to participants not taking insulin or antidiabetic medications (N = 
2,509). Fasting glucose, fasting insulin, HOMA-IR, and HbA1c levels were categorized into 
quartiles based on the weighted population distribution. 
We used multivariable logistic regression models to calculate odds ratios (OR) and 95% 
CI for the prevalence of glaucoma associated with glucose metabolism variables. Diabetes and 
pre-diabetes were included as exposures in the same model, and we fitted separate models for 
diabetes duration, metabolic syndrome and each its components, insulin resistance, fasting 
glucose, fasting insulin, HOMA-IR, and HbA1c. For each exposure, we used 3 models with 
progressive degrees of adjustment. Initial models were crude and then we adjusted for age, sex 
(male, female) and race/ethnicity (non-Hispanic, white, non-Hispanic black, Mexican 
American, and other). Finally, fully adjusted models further included education (< high school, 
high school, > high school), smoking (never, former, current), average physical activity level 
(low, medium, vigorous), alcohol drinking (< 1 drink/week, 1 to < 3 drinks/week, ≥3 





For dose-response analyses of the associations of fasting glucose, fasting insulin, 
HOMA-IR, and HbA1c levels with the prevalence of glaucoma, we calculated OR and 95% CI 
comparing quartiles 2 – 4 with the first quartile in categorical analyses, as well as OR and 95% 
CI comparing the 80th to the 20th percentiles of markers of glucose metabolism modeled as log-
transformed continuous variables. In addition, we used restricted cubic spline models with 
knots at the 10th, 50th and 90th percentiles of the distribution of fasting glucose, fasting insulin, 
HOMA-IR, and HbA1c concentrations to provide a smooth yet flexible description of the shape 
of dose-response relationship. Tests for non-linear trends computed by log likelihood ratio tests 
comparing nested models with and without non-linear spline terms. 
RESULTS 
The study population had a weighted mean (SE) age of 57.0 (0.4) years (Table 1). The 
prevalence of diabetes, pre-diabetes, metabolic syndrome, and insulin resistance were 17.1, 
49.0, 32.1, and 43.4%, respectively, and the prevalence of glaucoma was 4.2% (95 % CI 3.3 – 
5.3%). The average duration of diabetes was 11.8 years. Participants with prevalent glaucoma 
were more likely to be older, non-Hispanic black, less educated, and had higher waist 
circumference, blood pressure, fasting glucose and HbA1c levels (Table 1) and to have a 
significantly higher prevalence of diabetes, elevated blood pressure, and elevated fasting 
glucose (Table 2).  
The prevalence of glaucoma in participants with diabetes, with pre-diabetes, and 
without diabetes or pre-diabetes was 9.5, 3.5, and 2.6%, respectively (P < 0.001). In age-, sex-, 
and race / ethnicity-adjusted models, the OR for glaucoma comparing participants with diabetes 
to those without diabetes or pre-diabetes was 2.09 (95% CI 1.11 to 3.92) (Table 3).  The 





diabetes with glaucoma prevalence was stronger when the definition of diabetes was based on 
either fasting glucose or HbA1c levels only, with ORs of 2.12 (95% CI 1.23 to 3.67) and 2.10 
(95% CI 1.19 to 3.71), respectively. The fully adjusted OR (95% CI) for glaucoma comparing 
participants with pre-diabetes to those without diabetes or pre-diabetes was 0.88 (95% CI 0.45 
to 1.75). Diabetes duration was also significantly associated with glaucoma. Among 
participants with diabetes, the multivariable-adjusted OR for glaucoma comparing participants 
with a duration of disease ≥ 5 years to those with a duration of disease < 5 years was 3.90 (95% 
CI 1.63 to 9.32). 
The prevalence of glaucoma in patients with and without metabolic syndrome was 5.3 
and 3.6%, respectively (P = 0.06). The OR for glaucoma comparing participants with to those 
without metabolic syndrome was 1.30 (95% CI 0.83 to 2.03) in age-, sex-, and race / ethnicity-
adjusted models and 1.13 (95% CI 0.60 to 2.16) in fully adjusted models (Table 3).  In fully 
adjusted models, none of the individual components of the metabolic syndrome or the presence 
of insulin resistance were significantly associated with the prevalence of glaucoma (Table 3).  
In dose-response models with glucose biomarkers modeled as continuous variables or 
categorized in quartiles, the prevalence of glaucoma increased with increasing biomarker levels 
but the trends were only statistically significant for fasting glucose (Table 4). In fully adjusted 
models, the OR for glaucoma comparing the fourth to the first quartiles of fasting glucose, 
insulin, HOMA-IR, and HbA1C were 1.20 (95% CI 0.67 to 2.13; P trend 0.27), 1.22 (95% CI 
0.54 to 2.75; P trend 0.75), 1.37 (95% CI 0.57 to 3.27; P trend 0.19) and 1.55 (95% CI 0.59 to 
4.08; P trend 0.48), respectively. In spline models, however, the dose-response relationships 
between markers of glucose metabolism and the prevalence of glaucoma were hockey-stick 





values for the non-linear spline terms in the restricted cubic models were significant for all 
glucose biomarkers (p < 0.001 for all).  
DISCUSSION 
In a large sample representative of the general US population, the prevalence of 
glaucoma was higher in participants with diabetes compared to those with no glucose 
abnormality, even after controlling for multiple potential confounders. Pre-diabetes and the 
metabolic syndrome and its components were not consistently associated with the prevalence of 
glaucoma. However, markers of glucose metabolism showed significant non-linear associations 
with glaucoma prevalence, including hockey-stick shaped associations for fasting insulin, 
HbA1c and HOMA-IR, and a J-shaped association for fasting glucose. These non-linear 
relationships suggest threshold effects for the association of glucose metabolism markers and 
glaucoma. 
The association between diabetes and glaucoma has been evaluated in many studies 9,13–
15,17,29,30. An increased risk of glaucoma in persons with diabetes compared to those who did not 
have diabetes was also observed in the Beaver Dam Eye study, the Blue Mountains Eye study, 
the Los Angeles Latino Eye Study and several other population-based studies 3,5,16,19,31–35, but 
some well-known cohorts did not show statistically significant associations 9,14,17. The 
discrepancy with these studies may be attributed to study population, sample size, methods to 
assess diabetes or glaucoma, or drop-out rates. The Baltimore Eye Survey was primarily 
composed of African Americans and used self-report to define diabetes 9. The Rotterdam Study 
used a prospective cohort design, but had few participants with diabetes and a high drop-out 
rate, so that the results were based only on 5 incident cases of glaucoma among 264 





measurements instead of fasting glucose to define diabetes, which may result in substantial 
underdiagnosis, and had also limited power to identify an association beteween diabetes and 
glaucoma 17. In spite of these negative studies, the majority of the epidemiological evidence 
points to an increased prevalence of glaucoma in patients with diabetes. 
Few studies have evaluated the association between metabolic syndrome or glucose 
metabolism biomarkers and glaucoma, with conflicting results 16–19. In the Singapore Malay 
Eye Study, participants with metabolic syndrome had a lower prevalence of glaucoma 17, while 
the number of metabolic syndrome components was positively associated with the hazard of 
open-angle glaucoma in a US cohort 19. As for HbA1c and glucose, the Singapore Malay Eye 
Study showed an elevated but nonsignificant trend while a case-control study in Europe 
showed a significantly positive association between increased HbA1c levels and glaucoma 16. 
In our study, the association between glucose metabolism biomarkers and the prevalence of 
glaucoma was non-linear and affected only to participants in the higher half of the distribution 
of glucose metabolism parameters. These findings suggest that a certain degree of impairment 
in glucose metabolism is needed before glaucoma appears as a complication of insulin 
resistance.  
In addition to the level of glucose metabolism biomarkers, the duration of the metabolic 
abnormalities may also be important in determining glaucoma risk. We found that duration of 
diabetes was significantly associated with an increased prevalence of glaucoma, but we did not 
have information on the duration of the elevations in glucose metabolism biomarkers or on 
their trajectories over time. Additional research is needed to confirm these thresholds and to 






Several biological mechanisms could explain an increased risk of glaucoma in patients 
with diabetes. Diabetes may induce structural and functional abnormalities to the small blood 
vessels feeding the optic nerve, resulting in damage to the optic nerve and the retinal nerve 
fiber layer 36.  Besides the vascular implications, diabetes may also exacerbate glaucomatous 
optic neuropathy by increasing the susceptibility of retinal ganglion cells to apoptosis due to 
elevated intraocular pressure (IOP) 37. This mechanism may also explain progressive optic 
nerve injury and neuronal damage with a longer duration of diabetes. Furthermore, diabetic 
retinopathy may also compromise the glial and neuronal elements, impair retinal function and 
metabolism, and result in accelerated degeneration of retinal inner neurons 38. 
The potential mechanisms underlying the association between glucose metabolism 
abnormalities and the prevalence of glaucoma in subjects without diabetes are unclear. The 
presence of the metabolic syndrome and elevated levels of glucose, HOMA-IR and 
glycosylated hemoglobin may be associated with increased levels of IOP, a key causal factor 
for glaucoma 31,39–44. Hyperglycemia increased fibronectin production in the bovine trabecular 
meshwork, which may increase the resistance to aqueous humor outflow and lead to elevated 
IOP 45. Moreover, hyperglycemia could induce apoptosis in retinal neuronal cells through the 
hexosamine biosynthetic pathway 46. Additionally, hyperglycaemia-induced oxidative stress 
and advanced glycation end products may increase apoptotic death in retinal neurons 47,48. 
Several limitations need to be considered in the interpretation of our findings. First, the 
cross-sectional nature of this study limited our ability to establish the causality of the observed 
associations. Second, while we used high quality laboratory methods and fasting plasma 
samples to assess glucose metabolism status, the prevalence of glaucoma was assessed by self-





was similar to that reported in other US studies [46], the lack of a clinical assessment of 
glaucoma may have resulted in underdiagnosis and recall bias. Additional studies with high 
quality measurements of both glucose metabolism parameters and glaucoma status are needed 
to confirm our findings. Third, the increased prevalence of glaucoma in patients with diabetes 
and in those with longer duration of diabetes may have been overestimated because of more 
frequent ophthalmology visits in persons with compared to those without diabetes. We did not 
have information on the frequency of eye examinations in study participants, but other studies 
suggested that this type of surveillance bias could not completely account for the positive 
association between diabetes and glaucoma risk 5,31. In the Blue Mountains Eye study, most 
cases of glaucoma had been diagnosed before the diabetes diagnosis5, and the Nurses’ Health 
Study also showed that the prospective association between diabetes and glaucoma was 
unaltered when adjusting for factors related with the number of eye examinations 31. In spite of 
these limitations, the large sample size, the standardization and rigorous quality control 
procedures of NHANES, and the generalizability of the findings to the general US population 
are important strengths that add to the relevance of our findings. 
Glaucoma has a long latency period, in which glaucomatous optic nerve damage is 
ongoing but remains asymptomatic until later stages. Since vision loss is irreversible, screening 
and early detection of glaucoma is important in persons with diabetes, given the increased risk 
for glaucoma and the high frequency coexistence of other mechanisms for vision loss. The 
adherence to regular ophthalmological exams should be emphasized in diabetic patients, 
especially among those with long duration of diabetes, regardless of age. Our results also 
indicate that ophthalmologist referral may be considered for adults without diabetes but with 





In conclusion, data from NHANES 2005 – 2008, a large sample representative of the 
general US population, showed a higher prevalence of glaucoma in patients with diabetes, 
particularly in those with longer duration of disease, as well as an increased prevalence of 
glaucoma with increasing levels of glucose metabolism abnormalities in participants in the 
higher end of the distribution of glucose metabolism parameters. The mechanisms underlying 
these associations and the impact of the duration of glucose abnormalities on glaucoma risk 
need to be established in future studies. Our results support the recommendation that patients 
with diabetes, as well as those with elevated levels of glucose metabolism parameters, undergo 





Table 1. Characteristics of study participants by glaucoma status.* 
  Glaucoma p-value† 
 Overall 
N = 3,026 
No 
N = 2,835  
Yes 
N = 191 
Age, year 57.0 (0.4) 56.5 (0.4) 68.7 (1.5) < 0.001 
Female, % 53.2 (1.2) 53.2 (1.1) 52.3 (4.9) 0.87 
Race, %    0.009 
Mexican American 5.6 (0.8) 5.7 (0.8) 4.5 (1.6)  
NonHispanic white 76.2 (2.1) 76.4 (2.1) 71.6 (4.8)  
NonHispanic black 10.2 (1.4) 9.8 (1.4) 17.8 (3.7)  
Others 8.0 (1.1) 8.1 (1.1) 6.2 (2.5)  
Education, %    0.005 
< High school 18.5 (1.2) 18.0 (1.1) 29.0 (5)  
High school 27.0 (1.3) 26.9 (1.3) 30.6 (5.2)  
> High school 54.5 (2.1) 55.1 (2.1) 40.4 (4.9)  
Waist circumference, cm 100.3 (0.4) 100.2 (0.4) 103 (1.3) 0.04 
Systolic blood pressure, mm Hg 126.9 (0.5) 126.4 (0.5) 136.3 (2.2) < 0.001 
Diastolic blood pressure, mm Hg 70.7 (0.4) 70.9 (0.4) 65.7 (1.7) 0.005 
Body mass index, kg/m
2
 29.0 (0.1) 29.0 (0.1) 29.7 (0.5) 0.15 
Insulin, uU/mL ‡ 11.2 (0.3) 11.2 (0.3) 11.9 (1.1) 0.54 
Serum fasting glucose, mg/dL ‡ 103.5 (0.7) 103.4 (0.7) 108.6 (2.0) 0.01 
HDL, mg/dL 55.5 (0.3) 55.5 (0.3) 55.4 (1.5) 0.97 
Triglycerides, mg/dL 146.0 (2.7) 145.6 (2.7) 154.0 (12.7) 0.52 
HbA1c, % ‡ 5.5 (0.02) 5.5 (0.02) 5.7 (0.08) 0.01 
HOMA-IR ‡ 3.0 (0.1) 3.0 (0.1) 3.3 (0.4) 0.40 
* Data are means (SEs) or percentages (SEs). 
† P value for homogeneity of means or proportions comparing participants with to those without glaucoma. 










Table 2. Prevalence of glucose metabolism abnormalities by glaucoma status.* 
  Glaucoma p-value† 
 Overall 
N = 3,026 
No 
N = 2,835 
Yes 
N = 191 
Diabetes, % 17.1 (0.9) 16.1 (0.9) 38.8 (4.1) <0.001 
Prediabetes, % 49.0 (1.4) 49.4 (1.4) 40.4 (3.7) 0.34 
Insulin resistance, % 43.4 (1.5) 43.1 (1.5) 49.8 (4.7) 0.13 
Metabolic syndrome, % 32.1 (1.2) 31.7 (1.2) 41.1 (5.4) 0.06 
Elevated waist circumference, % 60.3 (1.4) 60.0 (1.4) 66.4 (4.1) 0.14 
Elevated blood pressure, % 42.1 (1.1) 41.1 (1.1) 63.3 (4.1) <0.001 
Elevated triglyceride, % 33.7 (0.9) 33.7 (1.0) 33.6 (5.5) 0.98 
Reduced HDL, % 24.0 (0.8) 24.2 (0.8) 18.0 (3.9) 0.17 
Elevated fasting glucose, % 28.8 (1.4) 28.2 (1.4) 43.3 (3.7) <0.001 
Duration of diabetes, years 11.7 (0.6) 11.3 (0.6) 15.2 (1.8) 0.04 
* Data are percentages or means (SEs). 







Table 3. Odds ratio and 95% CIs for the presence of glaucoma. 
 Crude model Model 1† Model 2‡ 
Diabetes    
HbA1c or fasting glucose* 3.99 (2.05, 7.76) 2.09 (1.11, 3.92) 1.80 (0.93, 3.47) 
Fasting glucose only§ 3.83 (2.24, 6.55) 2.28 (1.37, 3.81) 2.12 (1.23, 3.67) 
HbA1c only† 4.52 (2.65, 7.68) 2.65 (1.49, 4.71) 2.10 (1.19, 3.71) 
Prediabetes     
HbA1c or fasting glucose* 1.36 (0.72, 2.56) 0.96 (0.52, 1.75) 0.88 (0.45, 1.75) 
Fasting glucose only§ 1.23 (0.75, 2.02) 1.02 (0.63, 1.66) 1.01 (0.57, 1.82) 
HbA1c only† 2.63 (1.53, 4.51) 1.72 (0.98, 3.05) 1.57 (0.85, 2.92) 
Metabolic syndrome 1.50 (0.98, 2.29) 1.30 (0.83, 2.03) 1.13 (0.60, 2.16) 
Elevated waist circumference 1.31 (0.91, 1.90) 1.19 (0.81, 1.75) 0.89 (0.55, 1.45) 
Elevated blood pressure 2.47 (1.71, 3.56) 1.38 (0.97, 1.97) 1.39 (0.92, 2.09) 
Elevated triglyceride 0.99 (0.59, 1.68) 1.09 (0.65, 1.81) 0.90 (0.52, 1.57) 
Reduced HDL 0.69 (0.40, 1.18) 0.83 (0.47, 1.47) 0.73 (0.35, 1.52) 
Elevated fasting glucose 1.95 (1.40, 2.70) 1.35 (1.00, 1.83) 1.29 (0.85, 1.95) 
Diabetes duration > 5 years 2.48 (1.06, 5.76) 2.20 (1.02, 4.73) 3.90 (1.63, 9.32) 
Insulin resistance || 1.19 (0.78, 1.81) 1.22 (0.78, 1.90) 1.14 (0.64, 2.01) 
†Adjusted for age, gender, and ethnicity. 
‡Further adjusted for smoking, physical activity, alcohol intake, education, and BMI. 
* Diabetes defined as self-report, HbA1c ≥6.5%, fasting glucose ≥126 mg/dL, or taking diabetic 
medications. Pre-diabetes defined as self-report, HbA1c ≥5.7% to < 6.5%, or fasting glucose ≥100 mg/dL 
to <126 mg/dL. 
§Diabetes defined as self-report, HbA1c ≥6.5%, or taking diabetic medications. Pre-diabetes defined as 
self-report or HbA1c ≥5.7% to <6.5%. 
† Diabetes defined as self-report, fasting glucose ≥126 mg/dL or taking diabetic medications. Pre-diabetes 
defined as self-report or fasting glucose ≥100 mg/dL to <126 mg/dL. 






Table 4. Association between markers of glucose metabolism and the presence of glaucoma* 
 Odds ratio for glaucoma P value for 
quadratic 
trend 
 80th vs. 20th Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Fasting 
glucose 
      
Crude Model 1.37 (1.13, 1.64) 1.00 (reference) 0.71 (0.37, 1.34) 1.06 (0.55, 2.06) 1.56 (0.96, 2.56) 0.02 
Model 1† 1.22 (0.97, 1.54) 1.00 (reference) 0.67 (0.35, 1.29) 0.98 (0.51, 1.88) 1.05 (0.64, 1.72) 0.47 
Model 2‡ 1.30 (1.00, 1.68) 1.00 (reference) 0.67 (0.34, 1.34) 1.08 (0.47, 2.47) 1.20 (0.67, 2.13) 0.26 
Fasting 
Insulin 
      
Crude Model 1.06 (0.65, 1.73) 1.00 (reference) 1.00 (0.55, 1.81) 0.96 (0.44, 2.06) 1.14 (0.61, 2.15) 0.83 
Model 1† 1.16 (0.67, 2.01) 1.00 (reference) 1.02 (0.54, 1.90) 0.97 (0.44, 2.11) 1.32 (0.70, 2.49) 0.54 
Model 2‡ 1.13 (0.53, 2.41) 1.00 (reference) 0.92 (0.43, 1.98) 0.80 (0.30, 2.14) 1.22 (0.54, 2.75) 0.56 
HOMA-IR       
Crude Model 1.16 (0.70, 1.92) 1.00 (reference) 0.67 (0.34, 1.35) 1.36 (0.67, 2.76) 1.15 (0.61, 2.17) 0.24 
Model 1† 1.21 (0.70, 2.11) 1.00 (reference) 0.68 (0.34, 1.39) 1.39 (0.71, 2.71) 1.22 (0.64, 2.34) 0.17 
Model 2‡ 1.25 (0.57, 2.72) 1.00 (reference) 0.61 (0.28, 1.34) 1.27 (0.53, 3.05) 1.37 (0.57, 3.27) 0.22 
HbA1C       
Crude Model 1.43 (1.16, 1.77) 1.00 (reference) 1.43 (0.62, 3.31) 2.35 (0.95, 5.85) 3.91 (1.75, 8.71) 0.003 
Model 1† 1.23 (0.94, 1.60) 1.00 (reference) 1.10 (0.48, 2.51) 1.60 (0.61, 4.21) 1.86 (0.80, 4.28) 0.21 
Model 2‡ 1.15 (0.85, 1.55) 1.00 (reference) 0.96 (0.38, 2.40) 1.51 (0.53, 4.30) 1.55 (0.59, 4.08) 0.32 
* Conducted in people not taking diabetes medications. 
† Adjusted for age, gender, and ethnicity. 





Figure 1. Adjusted odds ratio for glaucoma by levels of markers of glucose metabolism. 
 
Adjusted odds ratios were estimated using restricted cubic splines with knots at the 10th, 
50th, and 90th percentiles of the distribution of each marker of glucose metabolism. The 
reference value (odds ratio = 1) was set at the 10th percentile of each parameter. Odds ratios 
were adjusted for age, sex, race, education, smoking status, physical activity, alcohol 
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Purpose: To examine the longitudinal association between age and intraocular pressure (IOP) 
in a large sample of Korean men and women. 
Methods: We conducted a prospective cohort study of  274,064 young and middle age Korean 
adults with normal fundoscopic findings followed from January 1, 2002 to Feb 28, 2010. 
Health exams were scheduled annually or biennially. At each visit, IOP was measured in both 
eyes with automated noncontact tonometers. The longitudinal change in IOP with age was 
evaluated using three-level mixed models for longitudinal paired-eye data accounting for 
correlations between paired eyes and repeated measurements over time. 
Results: In fully adjusted models, the average longitudinal change in IOP per one-year increase 
in age was -0.065 mm Hg (95% CI -0.068 to -0.063), with marked sex differences (P < 0.001). 
In men, the average annual IOP change was -0.093 mm Hg (95% CI -0.096 to -0.091) 
throughout follow-up. In women, the average annual IOP change was -0.006 mm Hg (95% CI -
0.010 to -0.003), with a relatively flat association in the middle-age range of 30–59 years and 
more marked annual decreases at younger and older ages.  
Conclusions: IOP was inversely associated with age in a large cohort of Korean adults, and 
this association was stronger in men compared with women. Further research is needed to 
better understand the underlying mechanisms and to reconsider cutoffs for defining high IOP 
by age and sex groups in Asian populations. 
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Elevated intraocular pressure (IOP) is a major risk factor for the development of 
primary open-angle glaucoma,1 and even in normal tension glaucoma the reduction of IOP may 
slow the progression of visual field loss.2 Population based studies of prevalence and incidence 
of glaucoma consistently show a steady increase with age.3-9 Consistent with this finding, 
cross-sectional and longitudinal studies have shown that IOP increases with age in Western 
populations. 2, 10-14 
In the 1980s, Shiose and Kawase reported an inverse association between age and IOP 
in a Japanese population,15, 16 and suggested that these results reflect ethnic differences or 
environmental effects. Several cross-sectional studies have confirmed these findings in 
Japanese17, 18 and in other East Asian populations,19-21 but the only two longitudinal prospective 
studies have been inconsistent. Nomura et al.22 reported that IOP significantly increased with 
age in Japanese men and women, while Nakano et al.23 reported that IOP decreased with age in 
young and middle-aged Japanese men.  The inconsistencies of these two studies could be 
because of the difference in study populations. Nomura et al. examined the association in 
69,643 Japanese office workers and their family members, while Nakano et al. selected 
participants from 2,987 Japanese male aircraft crew members. They also may be due to the 
methodological issues related to the analysis of the longitudinal IOP trajectories as Nomura et 
al. used a mixed effects model for longitudinal analysis, while Nakano et al. individually 
calculated coefficients for 11 measurement points using linear regression. 
Since cross-sectional studies do not provide estimates of within-subject IOP trajectories, 
we conducted a longitudinal cohort study to evaluate the influence of age on IOP in a large 






Study design and population 
The Kangbuk Samsung Health Study is a longitudinal cohort study of 281,238 adult 
Korean men and women who underwent comprehensive screening health examinations at the 
two Kangbuk Samsung Hospital Health Screening Centers in Seoul and Suwon, South Korea, 
from January 1, 2002, to February 28, 2010. Over 80% of the participants were employees of 
various companies or local government organizations and their spouses, who took employer-
paid annual or biennial health screening exams required by the Korean Industrial Safety and 
Health Law. The remaining participants voluntarily purchased screening exams at the health 
exam center. 
The present analysis included 280,911 study participants with valid IOP readings in at 
least one screening visit between January 1, 2002 and February 28, 2010 (the total number of 
visits was 604,416). We excluded 9,225 visits after participants developed an absolute 
difference in IOP between both eyes greater than 6 mm Hg, as this is a marker of high risk of 
glaucoma;24 1,652 visits with missing fundus photograph; 15,458 visits after participants 
developed abnormal findings in fundus photographs; and 100 visits for participants with 
missing IOP measurements at all visits . Thus, the final sample included 274,064 participants 
(119,723 women and 154,341 men) free of eye disease with a total of 577,981 screening visits. 
This study was approved by the Institutional Ethics Committee of the Kangbuk 
Samsung Hospital.  The Ethics Committee waived the requirement of informed consent as we 






Health exams were scheduled every 2 years for participants younger than 40 years of 
age and every year for participants 40 years of age or older. At each visit, IOP was measured in 
both eyes with automated noncontact tonometers (2002–2004: TX-10, Canon, Tokyo, Japan; 
2005–2008: TX-F, Topcon, Itabashi, Tokyo, Japan; 2009 onwards: CT-80, Topcon, Itabashi, 
Tokyo, Japan). Extreme IOP readings below 5 mm Hg (0.02%) or above 30 mm Hg (0.16%) 
were discarded because of the potential for measurement error. The time of registration at the 
exam center was within two hours of IOP measurement and hence used as the approximate IOP 
measurement time (classified into morning or afternoon). Fundus photographs were taken with 
a nonmydriatic fundus camera (CR6-45NM, Canon, Tokyo, Japan).  
Demographic characteristics, smoking status, alcohol consumption, physical activity, 
medical history, and medication use were collected by a standardized self-administered 
questionnaire.  Smoking status was categorized into never, former, or current smoking, 
frequency of current alcohol consumption was categorized into < 1, 1–3, or > 3 days/week, and 
frequency of vigorous physical activity was categorized into none, 1–3, or > 3 times/week. 
Height and weight were measured with the participants wearing a lightweight hospital gown 
and no shoes.  Body mass index was calculated as weight in kilograms divided by height in 
meters squared. Sitting blood pressure and heart rate were measured by trained nurses. 
Hypertension was defined as a systolic blood pressure ≥ 140 mm Hg, a diastolic blood pressure 
≥ 90 mm Hg, a self-reported history of hypertension, or current use of antihypertensive 
medications.  
Serum glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, and 
triglycerides were measured in fasting blood samples collected after at least 12 hours of fasting. 





of diabetes, or current use of antidiabetic medications. Dyslipidemia was defined as total 
cholesterol  ≥ 240 mg/dL, HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women, 
serum triglycerides ≥ 150 mg/dL, report of a previous diagnosis, or current use of lipid 
lowering medications.  
Statistical analysis 
The primary objective of this study was to assess the longitudinal change in IOP with 
age. To account for correlations in IOP measurements arising from both paired eyes and 
repeated measurements over time in the same participant, the main analyses consisted of three-
level linear mixed models for longitudinal paired-eye data.25, 26 Details of the models are 
provided in the Statistical Appendix. Briefly, we modeled linear trajectories in IOP with age 
for each eye at the first level, variations in IOP trajectories between both eyes of the same 
participant at the second level, and variations in IOP trajectories across participants at the third 
level. These mixed models provided the average longitudinal change in IOP per one-year 
increase in age, while they allowed for random variations in longitudinal changes among 
participants and between eyes within participants according to normal distributions with 
unstructured variance-covariance matrices. For comparison with previous studies, we also 
evaluated the cross-sectional association between age and IOP by using random-intercept linear 
models for paired-eye data from the baseline visit, which estimated the average cross-sectional 
difference in baseline IOP per one-year increase in baseline age. Details of cross-sectional 
analyses are also provided in the Statistical Appendix. 
To adjust for confounding and to evaluate potential mediating factors, we used three 
models with increasing degrees of adjustment. The first model was crude. The second model 





covariates, as well as for IOP measurement time (morning or afternoon), smoking status (never, 
former, or current), alcohol drinking (< 1, 1–3, or > 3 days/week), and physical activity (none, 
1–3, or > 3 times/week) as time-varying covariates. The third model further included potential 
mediators of the effect of age as time-varying covariates, including heart rate (continuous), 
body mass index (continuous), hypertension (no or yes), diabetes (no or yes), and dyslipidemia 
(no or yes). 
We accommodated distinct linear IOP trajectories in age intervals < 30, 30–39, 40–49, 
50–59, and  60 years by extending the above mixed models with fixed-effects linear spline 
terms for age at follow-up with knots at 30, 40, 50, and 60 years.27 Smooth longitudinal trends 
in IOP with age were also obtained by adding fixed-effects restricted quadratic spline terms for 
age with the same knots described above. To evaluate potential heterogeneity of IOP 
trajectories by sex, interactions of sex and age were included as fixed effects in the 
corresponding mixed models. We conducted sensitivity analyses without excluding participants 
with abnormal fundoscopy findings or with between-eye differences in IOP greater than 6 
mmHg (280,911 participants with 604,416 visits). In addition, we performed a sensitivity 
analysis restricted to participants with two or more screening visits (130,991 participants with 
435,262 visits). All reported P values were two-sided and the significance level was set at 0.05. 
Statistical analyses were undertaken using Stata (version 12; Stata Corp., College Station, 
Texas). 
RESULTS 
The mean (SD) age and IOP of study participants at baseline were 40.2 (9.9) years and 
13.6 (2.5) mm Hg, respectively (Table 1). Overall, women had lower mean baseline IOP levels 





participants older than 50 years of age.  Compared with men, women were less likely to smoke, 
drink alcohol, and exercise, and to have hypertension, diabetes, and dyslipidemia at baseline. 
Women had also lower mean baseline body mass index and higher heart rate.  Participants with 
two or more screening visits (n = 133,651) were generally younger, more educated, healthier, 
less likely to have diabetes, hypertension or dyslipidemia, and more likely to have a higher IOP 
compared with participants with only a single screening visit. 
In longitudinal analyses, age showed a significant inverse association with IOP (Table 
2). In fully adjusted models, the average longitudinal decrease in IOP for each one-year 
increase in age was -0.065 mm Hg (95% confidence interval [CI] -0.068 to -0.063 mm Hg). 
The longitudinal downward trend in IOP with increasing age, however, was markedly different 
between sexes and across age intervals (all P values < 0.001). For men, the average annual IOP 
change was -0.093 mm Hg (95% CI -0.096 to -0.091 mm Hg) over the entire age range and it 
varied from -0.142 to -0.080 mm Hg across the different age intervals. For women, the average 
annual IOP change was -0.006 mm Hg (95% CI -0.010 to -0.003 mm Hg) over the entire age-
range, with a relatively flat association between 30–59 years of age and more marked annual 
decreases of -0.167 and -0.076 mm Hg at younger and older ages, respectively. The 
longitudinal decrease in IOP with age and the differences between sexes were also evident in 
restricted quadratic spline models, which confirmed the homogeneous linear decline in men 
and the weaker nonlinear association in women (Figure 1). Sensitivity analyses restricting the 
study population to participants with at least two screening visits did not materially affect the 
result. Additional analyses without excluding participants with abnormal fundoscopy findings 






For comparison with previous studies, we also estimated the cross-sectional association 
between age and IOP at baseline. In cross-sectional analyses, age was also significantly 
inversely associated with IOP, although this baseline association was weaker than the 
longitudinal relationship (Supplementary Table 1 and Supplementary Figure 1). The 
average cross-sectional differences in baseline IOP per one-year increase in baseline age were -
0.023 mm Hg (95% CI -0.024 to -0.022 mm Hg) overall, -0.036 mm Hg (95% CI -0.037 to -
0.034 mm Hg) in men, and -0.008 mm Hg (95% CI -0.010 to -0.007 mm Hg) in women. 
DISCUSSION 
In this large cohort of Korean adults, IOP decreased with age but the decline was 
stronger in men compared with women and in participants <30 years of age compared with 
older participants. Cross-sectional associations between age and IOP followed a similar pattern, 
but underestimated the magnitude of the longitudinal association. The large sample size, the 
wide age range, the availability of repeated IOP measurements in both eyes in study 
participants, and the use of longitudinal analyses that consider the trajectories of individual 
eyes in each participant add to the strength of our findings.  
The inverse longitudinal and cross-sectional associations between age and IOP in our 
study are compatible with other cross-sectional16-19, 21, 28, 29 and longitudinal studies23 conducted 
in Asian populations with the exception of a longitudinal study in Japan.22 On the contrary, 
most cross-sectional2, 10, 30-33 and longitudinal studies34-36 in Western populations showed a 
positive association between age and IOP, although some studies showed no11, 37, 38 or inverse 
associations.39, 40 Aging is associated both with reduced production of aqueous humor,41 which 
leads to a reduction of IOP, and with structural changes in the trabecular meshwork, which 





be determined by the balance between these processes, which may differ in Western and Asian 
populations.  
The mechanisms for the differences in the association between age and IOP between 
Western and Asian populations are unclear. Lifestyle factors and environmental exposures have 
been proposed,22, 29, 35 but no single responsible factor has been clearly identified. Anatomical 
eye features linked to IOP (iris color, central corneal thickness, anterior chamber depth, etc.) 
could have different effects in Asian compared with Western subjects,23, 31, 39 but additional 
research is needed to understand the role of anatomical eye differences in IOP trajectories. 
Finally, the decrease in IOP with age in Asian populations has been ascribed to methodological 
factors such as selection bias due to non-participation in cross-sectional studies or drop out in 
longitudinal studies of elderly subjects with higher IOP and had higher comorbidities,22 or to 
cohort effects with younger individuals adopting Western lifestyles. In our study, however, we 
observed inverse associations between age and IOP even among participants <30 years of age, 
who are unlikely to be subject to selection bias due to major comorbidities. In addition the 
decrease in IOP with advancing age was observed across all age groups in the longitudinal 
analyses, with no clear cohort effects. 
Sex-related differences in the distribution of IOP and its changes with age have also 
been inconsistent across studies. In our study, women had a lower IOP compared with men, a 
pattern also reported in the the Egna-Neumarkt2 and the Gutenberg Health39 studies. In contrast, 
in the Barbados Eye study,30 the Rotterdam study43, the Los Angeles Latino Eye Study44 and 
the Beaver Dam Eye Study,11 men had lower IOP, while the Framingham Eye study33 and the 
Health and Nutrition Examination Survey45 reported no association between sex and IOP.  It 





cardiovascular risk factors in men.39, 44 However, adjusting for cardiovascular risk factors in our 
study did not materially change the association of IOP with age and sex.  
Hormonal differences and the effect of menopause may also explain some gender 
differences in IOP.46 Estrogen may affect the inflow of aqueous humour, the ciliary body and 
the trabecular meshwork.47 Indeed, an Indian study showed that the IOP in postmenopausal was 
higher compared with premenopausal women, and attributed this difference to the higher levels 
of testosterone and the decrease in estrogen and progesterone levels with the onset of 
menopause.48 Use of hormone replacement therapy has also been associated with a lower 
IOP.49, 50  Further research is needed to understand gender-related differences in IOP.  
Our study has several strengths. The Kangbuk Samsung Health Study is by far the 
largest population-based cohort study evaluating the association between age and IOP. The 
longitudinal nature allowed us to evaluate within-person trajectories in IOP, avoiding many 
biases in cross-sectional studies. The drop-out rate was modest (over 77% of participants 
recruited in the first year of the study had at least one additional follow-up visit), and we were 
able to incorporate multiple potential confounders and intermediate factors. Finally, we used a 
statistical approach based on a three-level hierarchical approach to appropriately account for 
correlations between eyes and between visits for each participant. 
Some limitations of our study also need to be considered. First, we used non-contact 
tonometers to measure IOP instead of applanation tonometers, considered the gold standard. 
This may have resulted in measurement error that may have underestimated study associations. 
Second, our study included preferentially young and middle-age adults, and only 6% of study 
participants had 60 years of age or over at baseline. Additional studies with follow-up of older 





decade of age in Asian populations. Finally, our study population consisted of middle-age 
Korean men and women attending health screening visits, which may limit the generalizability 
of our findings to other populations.  
In conclusion, we found that IOP was inversely associated with age in a large cohort of 
Korean adults attending health screening visits, an association that was stronger in men 
compared with women. Further research is needed to better understand the underlying 
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Table 1. Participants’ characteristics at baseline.* 
Characteristic Overall Female Male P value† 
Participants 274,064 119,723 (43.7) 154,341 (56.3) 
 Age, years 40.2 (9.9) 40.5 (10.3) 39.8 (9.5) < 0.001 
Study center  
  
< 0.001 
Seoul 184,957 (67.5) 81,423 (68.0) 103,534 (67.1) 
 Suwon 89,107 (32.5) 38,300 (32.0) 50,807 (32.9) 
 Height, cm 166.2 (8.5) 159.1 (5.5) 171.8 (5.9) < 0.001 
Smoking status  
  
< 0.001 
Never 147,039 (54.6) 105,391 (90.8) 41,648 (27.2) 
 Former 45,506 (16.9)  4,147 (3.6) 41,359 (27.0) 
 Current 76,582 (28.5)  6,497 (5.6) 70,085 (45.8) 
 Alcohol drinking, days/week  
  
< 0.001 
   < 1 172,819 (64.0) 101,902 (86.8) 70,917 (46.4) 
    1–3 71,097 (26.3) 12,732 (10.8) 58,365 (38.2) 
    > 3 26,319 (9.7)  2,824 (2.4) 23,495 (15.4) 
 Physical activity, times/week  
  
< 0.001 
   0 147,688 (54.6) 74,984 (63.5) 72,704 (47.6) 
    1–3 77,994 (28.8) 23,647 (20.0) 54,347 (35.6) 
    > 3 45,005 (16.6) 19,427 (16.5) 25,578 (16.8) 
 Heart rate, beats/min 67.2 (9.3) 68.3 (9.2) 66.4 (9.3) < 0.001 
Body mass index, kg/m2 23.5 (3.1) 22.4 (3.1) 24.4 (2.9) < 0.001 
Hypertension 47,671 (17.4) 14,501 (12.1) 33,170 (21.5) < 0.001 
Diabetes 10,763 (3.9)  3,416 (2.9)  7,347 (4.8) < 0.001 
Dyslipidemia 115,731 (42.2) 41,852 (35.0) 73,879 (47.9) < 0.001 
Intraocular pressure‡, mm Hg 13.58 (2.66) 13.10 (2.65) 13.95 (2.61) < 0.001 
   < 30 years 13.55 (2.71) 13.10 (2.71)  13.99 (2.64) < 0.001 
   30–39 years 13.58 (2.70) 12.94 (2.66)  14.05 (2.64) < 0.001 
   40–49 years 13.62 (2.60) 13.13 (2.58)  13.97 (2.55) < 0.001 
   50–59 years 13.59 (2.57) 13.52 (2.63)  13.66 (2.51) < 0.001 
    years 13.34 (2.62) 13.37 (2.67)  13.30 (2.57) 0.13 
* Data are means (SDs) or number (%). 
† P value for homogeneity of means or proportions comparing males and females. 
‡ Means (between-subject SDs) for the average intraocular pressure of left and right eyes overall and by 






Table 2. Longitudinal changes in intraocular pressure per 1-year increase in age, overall and by age interval.* 
  Age interval, years  
 Overall < 30 30–39 40–49 50–59  60 P value† 
No. of subjects/visits        
Overall   274,064 / 577,785     23,021 / 26,033    147,849 / 268,588     92,650 / 204,678     36,318 / 56,144     16,583 / 22,342  
Female   119,723 / 224,085     11,282 / 13,073     61,806 / 105,754     36,796 / 71,273     17,292 / 23,717      8,106 / 10,268  
Male   154,341 / 353,700     11,739 / 12,960     86,043 / 162,834     55,854 / 133,405     19,026 / 32,427      8,477 / 12,074  
Model 1§, mm Hg/year        
Overall -0.058 (-0.060 to -0.056) -0.128 (-0.141 to -0.115) -0.043 (-0.046 to -0.041) -0.073 (-0.076 to -0.069) -0.065 (-0.071 to -0.060) -0.104 (-0.112 to -0.095) < 0.001 
Female 0.000 (-0.003 to 0.004) -0.160 (-0.177 to -0.144) 0.005 (0.001 to 0.010) 0.004 (-0.001 to 0.009) 0.009 (0.000 to 0.017) -0.060 (-0.073 to -0.048) < 0.001 
Male -0.088 (-0.091 to -0.086) -0.118 (-0.138 to -0.098) -0.070 (-0.074 to -0.067) -0.105 (-0.109 to -0.101) -0.103 (-0.110 to -0.096) -0.124 (-0.135 to -0.112) < 0.001 
P value‡ < 0.001 0.001 < 0.001 < 0.001 < 0.001 < 0.001  
Model 2||, mm Hg/year        
Overall -0.059 (-0.061 to -0.057) -0.161 (-0.173 to -0.148) -0.046 (-0.049 to -0.043) -0.070 (-0.073 to -0.067) -0.061 (-0.067 to -0.056) -0.108 (-0.117 to -0.099) < 0.001 
Female 0.001 (-0.003 to 0.005) -0.170 (-0.186 to -0.153) 0.007 (0.002 to 0.011) 0.006 (0.001 to 0.012) 0.007 (-0.001 to 0.016) -0.065 (-0.079 to -0.052) < 0.001 
Male -0.087 (-0.090 to -0.085) -0.127 (-0.148 to -0.107) -0.071 (-0.074 to -0.067) -0.103 (-0.106 to -0.099) -0.103 (-0.110 to -0.095) -0.120 (-0.132 to -0.109) < 0.001 
P value‡ < 0.001 0.002 < 0.001 < 0.001 < 0.001 < 0.001  
Model 3¶, mm Hg/year        
Overall -0.065 (-0.068 to -0.063) -0.166 (-0.179 to -0.154) -0.054 (-0.056 to -0.051) -0.074 (-0.077 to -0.071) -0.073 (-0.078 to -0.067) -0.112 (-0.121 to -0.103) < 0.001 
Female -0.006 (-0.010 to -0.003) -0.167 (-0.184 to -0.151) 0.001 (-0.004 to 0.005) -0.001 (-0.007 to 0.004) -0.012 (-0.021 to -0.004) -0.076 (-0.089 to -0.063) < 0.001 
Male -0.093 (-0.096 to -0.091) -0.142 (-0.162 to -0.122) -0.080 (-0.083 to -0.076) -0.105 (-0.109 to -0.101) -0.108 (-0.115 to -0.101) -0.121 (-0.133 to -0.110) < 0.001 
P value‡ < 0.001 0.06 < 0.001 < 0.001 < 0.001 < 0.001  
* The average longitudinal changes in intraocular pressure per one-year increase in age and their 95% confidence intervals were obtained from linear mixed models with different 
intersecting linear trends in each age interval, interactions between linear age trends and sex, and random variations in linear age trends among participants and between eyes 
within participants. 
† P value for homogeneity of annual changes across all age intervals. 
‡ P value for homogeneity of annual changes comparing males and females. 
§ Unadjusted. 
|| Adjusted for study center (Seoul or Suwon), height (continuous), and time-varying changes in intraocular pressure measurement time (morning or afternoon), smoking status 
(never, former, or current), alcohol drinking (< 1, 1–3, or > 3 days/week), and physical activity (none, 1–3, or > 3 times/week). 







Figure 1. Longitudinal trend in intraocular pressure by age at follow-up. 
 
Curves represent adjusted average intraocular pressures (solid lines) and their 95% 
confidence intervals (dashed lines) based on restricted quadratic splines with knots at 30, 40, 50, 
and 60 years of age. Results were obtained from linear mixed models with interactions between 
spline terms and sex, random variations in age trends among participants and between eyes 
within participants, and adjusted for study center (Seoul or Suwon), height (continuous), and 
time-varying changes in intraocular pressure measurement time (morning or afternoon), 
smoking status (never, former, or current), alcohol drinking (< 1, 1–3, or > 3 days/week), 
physical activity (none, 1–3, or > 3 times/week), heart rate (continuous), body mass index 
(continuous), hypertension (no or yes), diabetes (no or yes), and dyslipidemia (no or yes). The 
histogram represents the age distribution of person-visits among males (shaded bars) and 






Supplemental Table 1. Cross-sectional changes in intraocular pressure per 1-year increase in age, overall and by age interval.* 
  Baseline age group, years  
 Overall < 30 30–39 40–49 50–59  60 P value† 
No. of subjects        
Overall 274,064 23,024 139,881 66,538 29,526 15,095  
Female 119,723 11,283 58,589 27,428 15,002 7,421  
Male 154,341 11,741 81,292 39,110 14,524 7,674  
Model 1§, mm Hg/year        
Overall -0.004 (-0.005 to -0.003) -0.045 (-0.058 to -0.033) 0.011 (0.008 to 0.015) -0.006 (-0.010 to -0.002) -0.001 (-0.007 to 0.005) -0.045 (-0.053 to -0.037) < 0.001 
Female 0.016 (0.014 to 0.017) -0.132 (-0.147 to -0.116) 0.019 (0.014 to 0.025) 0.031 (0.024 to 0.037) 0.030 (0.021 to 0.038) -0.047 (-0.059 to -0.035) < 0.001 
Male -0.019 (-0.020 to -0.017) -0.027 (-0.046 to -0.008) 0.004 (-0.001 to 0.008) -0.027 (-0.033 to -0.021) -0.028 (-0.036 to -0.020) -0.044 (-0.056 to -0.033) < 0.001 
P value‡ < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.75  
Model 2||, mm Hg/year        
Overall -0.008 (-0.009 to -0.007) -0.093 (-0.105 to -0.081) 0.007 (0.003 to 0.011) -0.006 (-0.010 to -0.001) -0.004 (-0.011 to 0.002) -0.057 (-0.065 to -0.048) < 0.001 
Female 0.010 (0.009 to 0.012) -0.146 (-0.162 to -0.130) 0.019 (0.014 to 0.025) 0.024 (0.018 to 0.031) 0.023 (0.014 to 0.033) -0.057 (-0.070 to -0.044) < 0.001 
Male -0.026 (-0.027 to -0.024) -0.042 (-0.061 to -0.023) -0.002 (-0.007 to 0.002) -0.032 (-0.038 to -0.026) -0.036 (-0.045 to -0.027) -0.048 (-0.060 to -0.037) < 0.001 
P value‡ < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.33  
Model 3¶, mm Hg/year        
Overall -0.023 (-0.024 to -0.022) -0.111 (-0.122 to -0.099) -0.005 (-0.009 to -0.002) -0.020 (-0.024 to -0.015) -0.025 (-0.031 to -0.019) -0.065 (-0.073 to -0.056) < 0.001 
Female -0.008 (-0.010 to -0.007) -0.158 (-0.173 to -0.142) 0.008 (0.002 to 0.013) 0.006 (-0.001 to 0.013) -0.005 (-0.014 to 0.004) -0.074 (-0.086 to -0.062) < 0.001 
Male -0.036 (-0.037 to -0.034) -0.061 (-0.080 to -0.042) -0.013 (-0.018 to -0.009) -0.041 (-0.047 to -0.035) -0.048 (-0.056 to -0.039) -0.052 (-0.064 to -0.041) < 0.001 
P value‡ < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.01  
* The average cross-sectional differences in baseline intraocular pressure per one-year increase in baseline age and their 95% confidence intervals were obtained from random-
intercept linear models for baseline paired-eye data with different intersecting linear trends in each baseline age group and interactions between linear age trends and sex. 
† P value for homogeneity of age slopes across all baseline age groups. 
‡ P value for homogeneity of age slopes comparing males and females. 
§ Unadjusted. 
|| Adjusted for study center (Seoul or Suwon), height (continuous), and baseline levels of intraocular pressure measurement time (morning or afternoon), smoking status (never, 
former, or current), alcohol drinking (< 1, 1–3, or > 3 days/week), and physical activity (none, 1–3, or > 3 times/week). 






Cross-sectional association of intraocular pressure with age at baseline 
The cross-sectional association between intraocular pressure (IOP) and age was 
evaluated by using random-intercept linear models for paired-eye data from the baseline visit.1 
More specifically, the IOP Y0ji at baseline visit t = 0 was allowed to vary randomly between 
eyes j = 1, 2 of each participant i = 1,…, n0, 
 Y0ji = 0i + 0ji, 
where 0i was the expected baseline IOP for participant i and 0ji was the between-eye 
variation in baseline IOP for that participant, which was assumed to be normally distributed 
with mean 0 and constant variance 2. The subject-specific baseline IOP 0i was related to 
baseline age a0i and other baseline x0i and time-constant covariates zi, including sex (male or 
female), study center (Seoul or Suwon), height (continuous), IOP measurement time (morning 
or afternoon), smoking status (never, former, or current), alcohol drinking (< 1, 1–3, or > 3 
days/week), physical activity (none, 1–3, or > 3 times/week), heart rate (continuous), body 
mass index (continuous), hypertension (no or yes), diabetes (no or yes), and dyslipidemia (no 
or yes), through the linear model 
 0i = 00 + 01(a0i  0a ) + 02(x0i  0x ) + 03(zi  z ) + b0i, 
where the between-subject variation b0i was assumed to be normally distributed with 
mean 0 and constant variance 2. Combining both models yielded the random-intercept linear 
model 





in which the fixed effect 00 represented the average baseline IOP at mean baseline 
values of age 0a  and covariates 0x  and z , the fixed effect 01 corresponded to the covariate-
adjusted average change in baseline IOP per one-year increase in baseline age, and the random 
effect b0i was the unexplained between-subject variation in baseline IOP. 
To allow for nonlinear cross-sectional associations between IOP and age, the above 
random-intercept model was separately extended with fixed-effects linear spline terms and 
restricted quadratic spline terms for baseline ages a0i with knots at 30, 40, 50, and 60 years and 
constrained to be 0 at the mean baseline age 0a .
2 Also, to evaluate potential heterogeneity of 
cross-sectional associations by sex, interactions of sex with the homogeneous linear term a0i  
0a , linear spline terms, and restricted quadratic spline terms were included as fixed effects in 
the corresponding random-intercept models. 
Longitudinal association of intraocular pressure with age 
To assess the longitudinal association of IOP with age, we developed linear mixed 
models for longitudinal paired-eye data using a three-level hierarchical approach.1 At the first 
within-eye level, the IOP Ytji at visit t = 0,…, mi for eye j = 1, 2 of participant i = 1,…, n0 was 
related to age ati and other subject-specific time-varying covariates xti at that visit through the 
linear model 
 Ytji = 0ji + 1ji(ati  a ) + 2ji(xti  x ) + tji, 
where 0ji was the expected IOP for eye j of participant i at the overall mean values of 
age a  and time-varying covariates x , 1ji and 2ji were the expected longitudinal slopes in 





time, smoking status, alcohol drinking, physical activity, heart rate, body mass index, 
hypertension, diabetes, and dyslipidemia, and the within-eye errors tji were assumed to be 
independent and normally distributed with mean 0 and constant variance 2. 
The second level represented the variation in coefficients 0ji, 1ji, and 2ji between 
eyes of the same participant. The eye-specific IOP at the overall mean covariates 0ji was 
allowed to vary randomly between each participant’s eyes, whereas the longitudinal slopes in 
IOP for age 1ji and the other time-varying covariates 2ji were assumed to be fixed for both 
eyes. Thus, the second-level model was 
 0ji = 00i + b0ji, 
 1ji = 10i, 
 2ji = 20i, 
where the between-eye variations within a subject b0ji were assumed to be normally 
distributed with mean 0 and constant variance 2. The longitudinal age slopes 1ji were 
specified as fixed at eye level because preliminary analyses showed virtually null random 
variation in longitudinal age slopes between each participant’s eyes. 
Finally, the third level described the variation in parameters 00i, 10i, and 20i across 
participants. The subject-specific IOP at the overall mean covariates 00i was linearly related to 
each participant’s mean values of age ia  and time-varying covariates ix , as well as to other time-
constant covariates zi, including sex, study center, and height. The subject-specific longitudinal 
age slopes in IOP 10i were allowed to vary randomly across participants, while the longitudinal 
slopes for the other time-varying covariates 20i were assumed to be constant for all participants. 





 00i = 000 + 001( ia   a ) + 002( ix   x ) + 003(zi  z ) + b00i, 
 10i = 100 + b10i, 
 20i = 200, 
where the between-subject variations b00i and b10i were assumed to follow a bivariate 
normal distribution with mean 0 and constant variance-covariance matrix V. Combining the 
three nested models, we obtained the linear mixed model 
 Ytji = (000 + b00i + b0ji) + 001( ia   a ) + 002( ix   x ) + 003(zi  z ) 
  + (100 + b10i)(ati  a ) + 200(xti  x ) + tji. 
This mixed model included two nested random effects for the intercept, as well as a 
random effect for the longitudinal age slope at subject level, to account for correlations arising 
from both paired-eye data and repeated measurements over time.3 In particular, the fixed effect 
000 represented the average IOP at the reference (overall mean) age for a subject with mean 
covariates, and the random effects b00i and b0ji were the unexplained variations in IOP at the 
reference age among participants and between eyes within participants, respectively. The fixed 
effect 100 corresponded to the average longitudinal change in IOP per one-year increase in age 
adjusted for time-varying covariates and the random effect b10i was the unexplained between-
subject variation in longitudinal age slopes. 
To allow for different longitudinal slopes in IOP in age intervals < 30, 30–39, 40–49, 
50–59, and  60 years, the above mixed model was extended with fixed-effects linear spline 
terms for age ati with knots at 30, 40, 50, and 60 years and constrained to be 0 at the overall 
mean age a .
2 The homogeneity of longitudinal slopes across age intervals was contrasted by 





simultaneously zero. In addition, to display the smooth longitudinal trend in IOP with age, the 
mixed model was also extended with fixed-effects restricted quadratic spline terms for age ati 
with the same knots and centering described above.2 
To evaluate potential heterogeneity of longitudinal age effects on IOP by sex, 
interactions of sex with the homogeneous linear term ati  a , linear spline terms, and 
restricted quadratic spline terms were included as fixed effects in the corresponding mixed 
models. Age-by-sex interactions were contrasted by performing joint Wald tests for all 
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Purpose: To examine the longitudinal and cross-sectional associations between body mass 
index (BMI), waist circumference, percent fat mass and intraocular pressure (IOP) in a large 
sample of Korean men and women. 
Methods: We conducted a prospective cohort study of 274,064 young and middle age Korean 
adults with normal fundoscopic findings followed from January 1, 2002 to Feb 28, 2010. 
Health exams were scheduled annually or biennially. At each visit, IOP was measured in both 
eyes with automated noncontact tonometers. The longitudinal change in IOP with body mass 
index, waist circumference and percent fat mass was evaluated using three-level mixed models 
for longitudinal paired-eye data accounting for correlations between paired eyes and repeated 
measurements over time. 
Results: In the fully adjusted models, the average longitudinal IOP increase for each 
interquartile change of BMI, waist circumference, and percent fat mass was 0.181mmHg (95% 
confidence interval [CI] 0.171 to 0.190), 0.269 mmHg (95% confidence interval [CI] 0.253 to 
0.284) and 0.100 mmHg (95% confidence interval [CI] 0.090 to 0.110), respectively, with 
marked sex differences (P < 0.001). The average cross-sectional differences in baseline IOP per 
interquartile increase in baseline BMI, waist circumference and percent fat mass were 0.393 
mmHg (95% CI 0.379 to 0.407), 0.434 mmHg (95% CI 0.412 to 0.456 mm Hg), and 0.428 
mmHg (95% CI 0.410 to 0.445 mm Hg).   
Conclusions: Adiposity was positively associated with increased IOP in a large cohort of 
Korean adults, and the association was evident in central obesity. Patients with elevated weight, 
or normal weight but excess central adiposity, could be identified and referred for eye 





heterogeneous effects by sex, and to establish evidence of weight reduction in terms of 
reducing IOP. 
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Intraocular pressure (IOP) is a key risk factor in the development and progression of 
primary open-angle glaucoma1, and IOP reduction or stabilization is the only proven method 
for glaucoma treatment.2 IOP is a complex trait influenced by multiple risk factors. Identifying 
potentially modifiable risk factors for IOP is crucial to understand the pathophysiology of 
glaucoma and develop strategies accordingly that may prevent the onset or improve the 
prognosis of the disease. 
Emerging evidences have suggested an association between elevated IOP and 
traditional cardiovascular (CVD) risk factors including age3-8, hypertension9-13 and diabetes14-17. 
Obesity or elevated body mass index (BMI), as a potential cause of hypertension and diabetes, 
have also shown independent positive associations with IOP in several cross-sectional17-20 and 
longitudinal5, 7, 21-25 studies. The cross-sectional studies could not establish the temporality of 
the association. And the previous longitudinal studies on the association between IOP and 
obesity were limited by small sample sizes, highly selective population, or short follow-up 
period. Another important weakness in the early cohort studies is the underdevelopment and 
usage of proper statistical methodology in assessing the longitudinal associations, resulting in 
inability to separate the cross-sectional with the longitudinal effects. In addition, no previous 
longitudinal study has assessed the association between central adiposity indicators (such as 
waist circumference and percent fat mass) with IOP levels. Central adiposity has been shown to 
be a better predictor of cardiovascular disease risk than BMI.26 There are important clinical 
implications if body shape or composition is better predictors of the IOP trajectory, compared 





The objective of this study is thus to evaluate the longitudinal association between 
changes in body adiposity markers (BMI, waist circumference and percent fat mass) and IOP 
over time in a cohort study of a large sample of healthy Korean men and women attending 
regular health screening visits. 
METHODS 
Study design and population 
The Kangbuk Samsung Health Study is a longitudinal cohort study of 281,238 Korean 
men and women 18 years of age or older who underwent comprehensive annual or biennial 
screening health examinations at the two Kangbuk Samsung Hospital Health Screening Centers 
in Seoul and Suwon, South Korea.27 Health exams were scheduled every 2 years for 
participants younger than 40 years of age and every year for participants 40 years of age or 
older from January 1, 2002, to February 28, 2010. Over 80% of the participants were 
employees of various companies or local government organizations and their spouses, who 
participated in annual or biennial health screening exams paid by employers under the Korean 
Industrial Safety and Health Law. The remaining participants voluntarily purchased self-paid 
screening exams at the health exam center. 
The present analysis included 280,911 study participants (number of visits was 604,416) 
who underwent tonometry as part of the comprehensive health examination between January 1, 
2002 and February 28, 2010. The following exclusion criteria were applied: visits after 
participants developed an absolute difference in IOP between both eyes greater than 6 mm Hg, 
as this is a marker of high risk of glaucoma (n=9,225 visits);28 visits with missing fundus 





photographs (n=15,458 visits). We further excluded participants with missing IOP 
measurements at all visits (n=100 visits). Thus, the final sample for this study included 274,064 
participants (119,723 women and 154,341 men) free of eye disease with a total of 577,981 
screening visits. The mean (SD) number of study visits per person was 2.2 (1.6). 
This study was approved by the Institutional Ethics Committee of the Kangbuk 
Samsung Hospital.  The requirement of informed consent was waived by the Ethics Committee 
as only de-identified data routinely collected during health screening visits were used. 
Measurements 
At each screening exam, IOP was measured with automated noncontact tonometers 
(2002–2004: TX-10, Canon, Tokyo, Japan; 2005–2008: TX-F, Topcon, Itabashi, Tokyo, Japan; 
2009 onwards: CT-80, Topcon, Itabashi, Tokyo, Japan) in both eyes. Extreme IOP readings 
below 5 mm Hg (0.02%) or above 30 mm Hg (0.16%) were set to missing because of the 
potential for measurement error. The IOP measurement time was approximated as the time of 
registration at the exam center and classified into morning or afternoon. Fundus photographs 
were taken with a nonmydriatic fundus camera (CR6-45NM, Canon, Tokyo, Japan).  
Height, weight, waist circumference and body composition were measured by trained 
nurses with the participants wearing a lightweight hospital gown and no shoes. BMI was 
calculated as weight in kilograms divided by height in meters squared. Waist circumference 
was measured at the midpoint between the bottom of the rib cage and above the top of the iliac 
crest to the nearest 0.1 cm while subjects were standing with their weight equally distributed on 
both feet, their arms at their sides, and head facing straight forward.  Waist circumference was 





measured using a multi-frequency bioimpedance analyzer (Inbody 3.0 and inbody 720, 
Biospace Co., Seoul, Korea).  
Demographic characteristics, smoking status, alcohol consumption, physical activity, 
medical history, and medication use were collected through standardized, self-administered 
questionnaires.  Smoking status was categorized into never, former, or current smoking, 
frequency of current alcohol consumption was categorized into < 1, 1–3, or > 3 days/week, and 
frequency of vigorous physical activity was categorized into none, 1–3, or > 3 times/week. 
Sitting blood pressure and heart rate were measured by trained nurses. Hypertension was 
defined as a systolic blood pressure ≥ 140 mm Hg, a diastolic blood pressure ≥ 90 mm Hg, a 
self-reported history of hypertension, or current use of antihypertensive medications.  
Blood specimens were sampled from the antecubital vein after at least 12 hours of 
fasting. Serum glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, and 
triglycerides were described in detail elsewhere.27 Diabetes mellitus was defined as a fasting 
serum glucose ≥ 126 mg/dL, a self-reported history of diabetes, or current use of antidiabetic 
medications.  
Statistical analysis 
We used several approaches to assess the longitudinal and cross-sectional associations 
between body adiposity markers and IOP. To control for the cross-sectional effect of baseline 
values while assessing the longitudinal associations between change in adiposity markers and 
IOP trajectory, the variables of baseline and change in adiposity markers were evaluated in the 
same model. We also accounted for the correlations in IOP measurements arising from both 
paired eyes and repeated measurements over time in the same participant. The main analyses 





models are provided in the Statistical Appendix. Briefly, we modeled linear associations in 
IOP with baseline adiposity markers and change in adiposity markers from baseline for each 
eye at the first level, variations in IOP trajectories between both eyes of the same participant at 
the second level, and variations in IOP slopes across participants at the third level.  
These mixed models provided the average cross-sectional difference in baseline IOP per 
1 unit increase in baseline adiposity markers, as well as the average longitudinal change in IOP 
per 1 unit increase in change of adiposity markers, while they allowed for random variations in 
longitudinal changes among participants and between eyes within participants according to 
normal distributions with unstructured variance-covariance matrices.  
To adjust for confounding and to evaluate potential mediating factors, we used three 
models with increasing degrees of adjustment. The first model adjusted for baseline age 
(continuous), change in age from baseline (continuous), sex (male or female) and study center 
(Seoul or Suwon). The second model further adjusted for potential confounding effects of 
height (continuous), as well as the baseline and time-varying changes in IOP measurement time 
(morning or afternoon), smoking status (never, former, or current), alcohol drinking (< 1, 1–3, 
or > 3 days/week), and physical activity (none, 1–3, or > 3 times/week). The third model 
further included potential mediators of the baseline and time-varying changes in hypertension 
(yes or no) and diabetes (yes or no). 
To allow for nonlinear cross-sectional and longitudinal relationships, we extended the 
above mixed models with linear cross-sectional and longitudinal spline terms. For the cross-
sectional association, we compared the baseline IOP across quartiles of the baseline adiposity 
markers with the first quartile; for the longitudinal association, we compared the longitudinal 





(constrained to be 0). In addition, we assessed the smooth cross-sectional and longitudinal IOP 
associations with adiposity markers using a restricted quadratic spline function of the baseline 
and change in adiposity markers with knots at the 5th, 50th, and 95th percentiles. To evaluate 
potential heterogeneity of the association between IOP and adiposity by sex, interactions of sex 
and adiposity were included as fixed effects in the mixed models.  
Additional analyses without excluding participants with abnormal fundoscopy findings 
or with between-eye differences in IOP greater than 6 mmHg (280,911 participants with 
604,416 visits) were conducted. In addition, we performed a sensitivity analysis restricted to 
participants with two or more screening visits (130,991 participants with 435,262 visits). All 
reported P values were two-sided and the significance level was set at 0.05. Statistical analyses 
were undertaken using Stata (version 12; Stata Corp., College Station, Texas). 
RESULTS 
The mean (SD) BMI, waist circumference, percent fat mass, and IOP of study 
participants at baseline were 23.5 (3.2) kg/m2, 79.8 (9.5) cm, 24.9 (6.4) % and 13.5 (2.7) 
mmHg, respectively (Table 1). Participants who had higher baseline IOP were generally older, 
higher, more likely to be males, smokers, alcohol drinkers, and had higher heart rate, blood 
pressures, cholesterol levels, fasting glucose, BMI, waist circumference and percent fat mass 
compared with participants with the lowest quartile of IOP levels. 
Over the 8 year follow-up, the mean (SD) change in IOP from baseline was -0.12 (1.45). 
Longitudinally, IOP was positively associated with the changes in all body adiposity markers 
(Table 2). Adjusting for hypertension and diabetes as mediators (Model 3) did not substantially 
reduce the effect sizes. The median (interquartile range) in changes of BMI, waist 





0.29 (-1.39, 2.00), respectively. In the fully adjusted models, the average longitudinal IOP 
increase for each interquartile change of BMI, waist circumference, and percent fat mass was 
0.181mmHg (95% confidence interval [CI] 0.171 to 0.190), 0.269 mmHg (95% confidence 
interval [CI] 0.253 to 0.284) and 0.100 mmHg (95% confidence interval [CI] 0.090 to 0.110), 
respectively. Compared with baseline values, IOP decreased with decreasing body adiposity 
levels. The positive longitudinal associations in IOP with change in body adiposity markers 
were also evident in restricted quadratic spline models, which showed a relatively marked slope 
for change in waist circumference and BMI, and a flatter slope for change in percent fat mass 
(Figure 1). 
Cross-sectioinally, baseline IOP was also significantly positively associated with 
baseline adiposity markers, with a stronger effect than the longitudinal associations 
(Supplementary Table 1 and Supplementary Figure 1). After adjusting for hypertension and 
diabetes as mediators (Model 3), the effect size reduced but remained significant. The average 
cross-sectional differences in baseline IOP per interquartile increase in baseline BMI, waist 
circumference and percent fat mass were 0.393 mmHg (95% CI 0.379 to 0.407), 0.434 mmHg 
(95% CI 0.412 to 0.456 mm Hg), and 0.428 mmHg (95% CI 0.410 to 0.445 mm Hg). 
Interestingly, the longitudinal associations between adiposity and IOP were somewhat 
stronger in men than in women while the cross-sectional associations were weaker in men than 
in women (Figure 2). Additional analyses without excluding participants with abnormal 
fundoscopy findings or with between-eye differences in IOP greater than 6 mmHg yielded 
similar results. Sensitivity analyses restricting the study population to participants with at least 






In this large cohort of Korean adults, IOP was positively associated with body mass 
index, waist circumference and percent fat mass both longitudinally and cross-sectionally. BMI 
and waist circumference were better longitudinal predictors for IOP vs. percent fat mass. The 
decrease in body adiposity levels had a greater impact on IOP reduction in men than women. 
The cross-sectional associations between body adiposity and IOP followed the same pattern but 
were more evident than the longitudinal associations. These associations were independent of 
conventional cardiovascular risk factors including hypertension and diabetes. This is also the 
first study that assessed the longitudinal associations between central obesity and IOP. The 
strength of our study include large sample size, the wide range in baseline and change of 
adiposity, the availability of repeated IOP measurements in both eyes in study participants, and 
the use of longitudinal analyses that controlled for the cross-sectional effects.  
The positive association between IOP and BMI was also reported in other longitudinal 
studies conducted in Japan, China, and West Indies.5, 7, 21-25 However, some limitations existed 
in previous studies that warrant the current analyses. The Beijing Eye study22 and another 
Japanese study24 had small sample size (2257 Chinese and 896 Japanese individuals) and had 
only two measurements 5 years apart. Two other studies in Japan23, 25 and the Barbados Eye 
Study7 mainly aimed at assessing the association between age, other systemic risk factors with 
IOP, and BMI was included as a covariate in the multivariate regression but not studied in 
depth. The other Japanese study found the positive association between slope of IOP with slope 
of BMI but did not estimate the relative magnitude of IOP change associated with absolute 
change in BMI.21 
Several mechanisms may explain an increase in IOP with higher adiposity. The 





thereby causing a rise in IOP as a consequence of impaired aqueous humor outflow facility.31, 32 
In addition, obesity-related diseases, such as high blood pressures and diabetes, may serve as 
mediators on the pathway between obesity and IOP. Increased blood pressure increased 
filtration of aqueous humor through elevated capillary pressure and reduced aqueous humor 
outflow through elevated episcleral venous pressure.33 Hyperglycemia may induce an osmotic 
gradient that shifts excess aqueous humor into the anterior chamber.34 Both can ultimately lead 
to elevated IOP. This is also supported by our results that the association between IOP and 
adiposity was weaker after adjusting for hypertension and diabetes. Obesity is also a risk factor 
for vascular endothelial dysfunction and autonomic dysfunction35, 36, which are associated with 
abnormal ocular blood flow and perfusion instability. Furthermore, obesity-related oxidative 
stress may cause trabecular meshwork degeneration, impair the ability of the intracellular tissue 
to modulate outflow resistance, and results in IOP elevation.37 
The impact of change in anthropometric parameters on IOP was stronger in waist 
circumference compared with BMI, suggesting that central adiposity, particularly a greater 
amount of intraabdominal or visceral fat, may be better predictor of risk of high IOP than the 
other anthropometric measures. On the other hand, the weaker change in IOP associated with 
percent fat mass may be due to the fact that the percent fat mass is a measurement of 
subcutaneous adiposity, but not indicative of fat distribution or visceral fat accumulation. This 
result suggested that patients with normal BMI but who are centrally obese are also at risk for 
high IOP and could be recommended to undergo routine screening for glaucoma.  
Clear pathophysiological explanation for the gender differences of the association 
between IOP and adiposity is currently lacking. A possible reason is the difference in body fat 





adipose tissue than women.38 Hormonal differences may explain the heterogeneity by sex.39 
Estrogen levels increase with increasing adipose, and may affect the inflow of aqueous humour, 
the ciliary body and the trabecular meshwork.40, 41 Further research is needed to understand 
gender-related differences in IOP and adiposity.  
Weight loss has been proven to be an effective strategy in reducing the risk for many 
health problems such as hypertension and diabetes, but it was not considered a standard 
approach in glaucoma treatments. In our study, weight loss was associated with IOP reduction 
over time, and therefore could potentially become a lifestyle or therapeutic intervention in 
lowering IOP, the objective in all current glaucoma treatments. Nevertheless, the effect of 
weight loss on IOP reduction and glaucoma prognosis has never been evaluated in clinical trials.  
Future clinical trials are needed to assess the role of weight management in IOP reduction 
among obese patients, or patients with normal-weight central obesity. 
Our study has several strengths. First, the Kangbuk Samsung Health Study is by far the 
largest population-based cohort study evaluating the association between adiposity and IOP. 
Second, the longitudinal structure permitted us to evaluate within-person changes in IOP 
related with adiposity changes, avoiding biases commonly seen in cross-sectional studies. Third, 
the retaining of participants was fair (over 77% of participants recruited in the first year of the 
study had at least one additional follow-up visit). Fourth, besides BMI, repeated measurements 
of waist circumference and percent fat mass was also appraised, and we were able to 
incorporate multiple potential confounders and intermediate factors, allowing for a detailed 
characterization of the association between central obesity, subcutaneous adiposity and IOP. 
Finally, we used a statistical approach that controlled for baseline effect while obtaining the 





hierarchical approach to appropriately account for correlations between eyes and between visits 
for each participant. 
Some limitations of our study also need to be considered. First, we used non-contact 
tonometers to measure IOP. This may have resulted in measurement error that may 
underestimate study associations compared with applanation tonometers, the gold standard. 
Second, our study included preferentially young and middle-age adults below 60 years of age, 
and only 6% of study participants were 60 years of age or over at baseline, which may limit our 
ability to make inference on the relationship of adiposity with IOP in elder populations. Finally, 
our study population consisted of apparently healthy middle-age Korean men and women 
attending health screening visits, which may limit the generalizability of our findings to other 
populations.  
In conclusion, we found that excess adiposity was associated with significantly 
increased IOP in a large cohort of Korean adults attending health screening visits, an 
association that was stronger in central obesity. As a consequence, patients with elevated 
weight, or normal weight but excess central adiposity, could be identified and referred for eye 
screening. Further research is needed to better understand the underlying mechanisms of the 
heterogeneous effects by sex, and to establish evidence of weight reduction in terms of 






Table 1. Participants’ characteristics at baseline.* 
Characteristic   Intraocular pressure†  










Participants 274,136 71206 77036 68777 56503 
Intraocular pressure†, mm Hg 13.5±2.7 10.3±1.0 12.8±0.6 14.7±0.6 17.4±1.4 
Age, years 40.1±10.0 40.2±10.2 40.3±10.1 40.1±9.9 39.7±9.8 
Male 153,964 
(56.3) 
31,521 (44.3) 42,788 (55.5) 43,042 (62.6) 36,613 (64.8) 
Study center      
   Seoul 184,579 
(67.5) 
47,876 (67.2) 53,146 (69.0) 47,838 (69.6) 35,719 (63.2) 
   Suwon 88,943 (32.5) 23,330 (32.8) 23,890 (31.0) 20,939 (30.4) 20,784 (36.8) 
Smoking status      
   Never 146,797 
(54.7) 
43,791 (62.7) 41,828 (55.3) 34,131 (50.5) 27,047 (48.7) 
   Former 45,385 (16.9) 9,833 (14.1) 12,828 (17.0) 12,378 (18.3) 10,346 (18.6) 
   Current 76,411 (28.4) 16,212 (23.2) 20,985 (27.7) 21,111 (31.2) 18,103 (32.6) 
Alcohol drinking, days/week      
   < 1 172,507 
(64.0) 
49,438 (70.4) 49,177 (64.7) 41,129 (60.6) 32,763 (58.8) 
   1–3 70,964 (26.3) 15,563 (22.2) 19,570 (25.8) 19,241 (28.4) 16,590 (29.8) 
   > 3 26,231 (9.7) 5,210 (7.4) 7,206 (9.5) 7,490 (11.0) 6,325 (11.4) 
Physical activity, times/week      
   0 147,395 
(54.6) 
39,622 (56.4) 41,546 (54.6) 36,368 (53.5) 29,859 (53.5) 
   1–3 77,858 (28.8) 18,736 (26.7) 21,950 (28.8) 20,377 (30.0) 16,795 (30.1) 
   > 3 44,899 (16.6) 11,937 (17.0) 12,620 (16.6) 11,223 (16.5) 9,119 (16.4) 
Height, cm 166.1±8.6 165.2±8.4 166.1±8.6 166.7±8.6 166.7±8.6 
Heart rate, beats/min 67.1±9.3 65.6±8.7 66.7±9.0 67.7±9.4 69.0±10.0 
Body mass index, kg/m2 23.5±3.2 22.8±3.0 23.4±3.1 23.8±3.2 24.2±3.3 
Waist circumference, cm 79.8±9.5 77.4±9.3 79.6±9.4 81.0±9.3 81.7±9.4 
Percent fat mass, % 24.9±6.4 24.9±6.4 24.8±6.4 24.8±6.4 25.3±6.4 
Diabetes 10,707 (3.9) 1,615 (2.3) 2,485 (3.2) 2,976 (4.3) 3,631 (6.4) 
Fasting Glucose, mg/dL 95.2±16.8 92.5±12.5 94.5±15.2 96.2±17.4 98.7±21.6 
Total cholesterol, mg/dL 194.6±35.2 189.8±34.2 193.8±34.8 196.4±35.2 199.7±36.1 
HDL, mg/dL 55.3±12.4 56.2±12.8 55.4±12.4 54.9±12.2 54.5±12.1 
LDL, mg/dL 112.4±29.8 108.8±29.0 111.8±29.5 113.8±29.8 116.3±30.5 
Triglycerides, mg/dL 126.8±86.1 110.7±71.8 124.0±82.6 133.6±91.7 143.3±96.6 
Hypertension 47,494 (17.4) 8,247 (11.6) 12,161 (15.8) 13,343 (19.4) 13,743 (24.3) 
SBP, mm Hg 114.8±14.6 111.2±13.6 114.1±14.0 116.3±14.5 118.8±15.3 
DBPmm Hg 74.3±10.0 71.8±9.5 73.9±9.8 75.4±10.0 76.9±10.4 
* Data are means±SDs or number (%). 






Table 2. Longitudinal associations between intraocular pressure and change of adiposity markers 
 Interval of change compared with baseline   
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Interquartile range ‡ P value† 
Change in BMI, kg/m2       
   No. of subjects/visits 45881/75937 54132/75938 54195/75937 45363/75937 130855/303749  
   Median (range) -1.00 (-11.35, -0.49) -0.15 (-0.49, 0.14) 0.43 (0.14, 0.77) 1.26 (0.77, 11.76) 0.14 (-0.49, 0.77)  
   Model 1§ -0.255 (-0.272, -0.238) -0.097 (-0.113, -0.081) -0.007 (-0.022, 0.009) 0.145 (0.127, 0.163) 0.203 (0.193, 0.212) <0.001 
   Model 2|| -0.214 (-0.232, -0.197) -0.079 (-0.095, -0.062) 0.004 (-0.012, 0.020) 0.138 (0.120, 0.157) 0.181 (0.172, 0.191) <0.001 
   Model 3¶ -0.212 (-0.230, -0.195) -0.075 (-0.091, -0.059) 0.007 (-0.009, 0.023) 0.140 (0.122, 0.158) 0.181 (0.171, 0.190) <0.001 
Change in waist circumference, cm       
   No. of subjects/visits 20431/30392 23123/30142 23139/30003 20619/30313 59459/120850  
   Median (range) -4.50 (-54.80, -2.30) -0.70 (-2.30, 0.80) 2.20 (0.80, 3.90) 6.10 (3.90, 40.20) 0.80 (-2.30, 3.90)  
   Model 1§ -0.381 (-0.408, -0.354) -0.171 (-0.197, -0.146) -0.037 (-0.062, -0.011) 0.120 (0.093, 0.146) 0.286 (0.271, 0.301) <0.001 
   Model 2|| -0.354 (-0.382, -0.327) -0.160 (-0.186, -0.134) -0.038 (-0.064, -0.012) 0.117 (0.090, 0.144) 0.270 (0.255, 0.285) <0.001 
   Model 3¶ -0.352 (-0.380, -0.324) -0.159 (-0.185, -0.133) -0.037 (-0.063, -0.011) 0.118 (0.091, 0.145) 0.269 (0.253, 0.284) <0.001 
Change in percent fat mass, %       
   No. of subjects/visits 42564/65369 47794/65369 47721/65368 42358/65369 117867/261475  
   Median (range) -2.70 (-60.47, -1.39) -0.49 (-1.39, 0.29) 1.08 (0.29, 2.00) 3.35 (2.00, 31.56) 0.29 (-1.39, 2.00)  
   Model 1§ -0.165 (-0.183, -0.147) -0.080 (-0.097, -0.063) -0.032 (-0.049, -0.014) 0.080 (0.061, 0.099) 0.126 (0.117, 0.136) <0.001 
   Model 2|| -0.122 (-0.141, -0.103) -0.058 (-0.076, -0.040) -0.021 (-0.039, -0.003) 0.072 (0.053, 0.092) 0.103 (0.093, 0.113) <0.001 
   Model 3¶ -0.117 (-0.136, -0.098) -0.054 (-0.071, -0.036) -0.018 (-0.036, -0.001) 0.073 (0.053, 0.092) 0.100 (0.090, 0.110) <0.001 
* Obtained from linear mixed models with different intersecting linear trends in each quartile interval, and random variations in linear trends among participants and between eyes 
within participants. 
‡ The average longitudinal changes and their 95% confidence intervals in intraocular pressure with interquartile change in body weight markers (1.26 kg/m2 for BMI, 6.20 cm for 
waist circumference, 3.40% for percent fat mass, 3.21% for percent muscle mass)  
† P value for homogeneity of annual changes across all quartile intervals. 
§ Adjusted for baseline age (continuous), change in age (continuous), sex (male or female), and study center (Seoul or Suwon). 
|| Further adjusted for height (continuous), baseline and time-varying changes in intraocular pressure measurement time (morning or afternoon), smoking status (never, former, or 
current), alcohol drinking (< 1, 1–3, or > 3 days/week), physical activity (none, 1–3, or > 3 times/week) and heart rate (continuous). 







Figure 1. Longitudinal associations between intraocular pressure and change in body adiposity over time. 
 
Curves represent adjusted average change in intraocular pressures (solid lines) and their 95% confidence intervals (dashed lines) based on 
restricted quadratic splines with knots at 5th, 50th and 95th percentile. Results were obtained from linear mixed models with random variations in IOP 
changes among participants and between eyes within participants, and adjusted for baseline adiposity marker levels (continuous), sex (male or 
female), study center (Seoul or Suwon), height (continuous), and baseline and time-varying changes in age(continuous), intraocular pressure 
measurement time (morning or afternoon), smoking status (never, former, or current), alcohol drinking (< 1, 1–3, or > 3 days/week), physical activity 
(none, 1–3, or > 3 times/week), heart rate (continuous),  hypertension (no or yes), and diabetes (no or yes). The histogram represents the body 







Figure 2. Longitudinal associations between intraocular pressure and change in body adiposity over time, by sex. 
 
Curves represent adjusted average change in intraocular pressures (solid lines) and their 95% confidence intervals (dashed lines) based on 
restricted quadratic splines with knots at 5th, 50th and 95th percentile. Results were obtained from linear mixed models with interactions between 
spline terms and sex, random variations in IOP trends among participants and between eyes within participants, and adjusted for baseline adiposity 
marker levels (continuous), sex (male or female), study center (Seoul or Suwon), height (continuous), and baseline and time-varying changes in 
age(continuous), intraocular pressure measurement time (morning or afternoon), smoking status (never, former, or current), alcohol drinking (< 1, 1–







Supplemental Table  1. Cross-sectional associations between intraocular pressure and baseline body adiposity 
 Baseline intervals compared with 1st quartile   
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Interquartile range ‡ P value† 
Baseline BMI, kg/m2       
   No. of subjects 68513 68508 68510 68510 274041  
   Median (range) 19.93 (13.66, 21.27) 22.37 (21.27, 23.37) 24.37 (23.37, 25.51) 27.07 (25.51, 61.44) 23.37 (21.27, 25.51)  
   Model 1§ Reference 0.275 (0.248, 0.303) 0.533 (0.504, 0.561) 0.951 (0.922, 0.980) 0.509 (0.496, 0.523) <0.001 
   Model 2|| Reference 0.257 (0.230, 0.284) 0.490 (0.462, 0.518) 0.860 (0.831, 0.889) 0.458 (0.444, 0.472) <0.001 
   Model 3¶ Reference 0.249 (0.222, 0.276) 0.452 (0.424, 0.480) 0.744 (0.715, 0.774) 0.393 (0.379, 0.407) <0.001 
Baseline waist circumference, cm       
   No. of subjects 42421 39421 38225 39821 159888  
   Median (range) 68.60 (36.00, 73.00) 77.00 (73.10, 80.00) 83.20 (80.10, 86.40) 90.80 (86.50, 142.00) 80.00 (73.00, 86.40)  
   Model 1§ Reference 0.392 (0.356, 0.427) 0.640 (0.600, 0.679) 0.902 (0.861, 0.943) 0.519 (0.498, 0.540) <0.001 
   Model 2|| Reference 0.381 (0.345, 0.417) 0.616 (0.576, 0.656) 0.885 (0.843, 0.927) 0.511 (0.490, 0.533) <0.001 
   Model 3¶ Reference 0.362 (0.326, 0.398) 0.557 (0.517, 0.596) 0.754 (0.712, 0.796) 0.434 (0.412, 0.456) <0.001 
Baseline percent fat mass, %       
   No. of subjects 63768 63764 63758 63760 255050  
   Median (range) 17.79 (1.25, 20.44) 22.49 (20.44, 24.46) 26.61 (24.46, 29.25) 32.57 (29.25, 78.52) 24.46 (20.44, 29.25)  
   Model 1§ Reference 0.341 (0.313, 0.369) 0.569 (0.540, 0.599) 1.024 (0.990, 1.057) 0.605 (0.588, 0.622) <0.001 
   Model 2|| Reference 0.274 (0.246, 0.302) 0.446 (0.416, 0.475) 0.825 (0.790, 0.859) 0.497 (0.479, 0.514) <0.001 
   Model 3¶ Reference 0.226 (0.198, 0.254) 0.365 (0.335, 0.395) 0.703 (0.669, 0.738) 0.428 (0.410, 0.445) <0.001 
* Obtained from linear mixed models with different intersecting linear trends in each quartile interval, and random variations in linear trends among participants and 
between eyes within participants. 
‡ The average longitudinal changes and their 95% confidence intervals in intraocular pressure with interquartile change in body weight markers (4.24 kg/m2 for BMI, 
13.40 cm for waist circumference, 8.81% for percent fat mass, 8.53% for percent muscle mass)  
† P value for homogeneity of annual changes across all quartile intervals. 
§ Adjusted for baseline age (continuous), change in age (continuous), sex (male or female), study center (Seoul or Suwon). 
|| Further adjusted for height (continuous), baseline and time-varying changes in intraocular pressure measurement time (morning or afternoon), smoking status (never, 
former, or current), alcohol drinking (< 1, 1–3, or > 3 days/week), physical activity (none, 1–3, or > 3 times/week) and heart rate (continuous). 






Supplemental Figure 1. Cross-sectional associations between baseline intraocular pressure and baseline body adiposity 
 
Curves represent adjusted difference in baseline intraocular pressures (solid lines) and their 95% confidence intervals (dashed lines) across 
spectrum of baseline body adiposity marker levels compared with the 10th percentile based on restricted quadratic splines with knots at 5th, 50th and 
95th percentile. Results were obtained from linear mixed models with random variations in IOP among participants and between eyes within 
participants, and adjusted for sex (male or female), study center (Seoul or Suwon), height (continuous), time-varying changes in adiposity markers 
(continuous), and baseline and time-varying changes in age(continuous), intraocular pressure measurement time (morning or afternoon), smoking 
status (never, former, or current), alcohol drinking (< 1, 1–3, or > 3 days/week), physical activity (none, 1–3, or > 3 times/week), heart rate 







Supplemental Figure 2. Cross-sectional associations between baseline intraocular pressure and baseline body adiposity, by sex 
 
 
Curves represent adjusted difference in baseline intraocular pressures (solid lines) and their 95% confidence intervals (dashed lines) across 
spectrum of baseline body adiposity marker levels compared with the 10th percentile based on restricted quadratic splines with knots at 5th, 50th and 
95th percentile. Results were obtained from linear mixed models with interactions between spline terms and sex, random variations in IOP among 
participants and between eyes within participants, and adjusted for sex (male or female), study center (Seoul or Suwon), height (continuous), time-
varying changes in adiposity markers (continuous), and baseline and time-varying changes in age(continuous), intraocular pressure measurement 
time (morning or afternoon), smoking status (never, former, or current), alcohol drinking (< 1, 1–3, or > 3 days/week), physical activity (none, 1–3, 
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Cross-sectional and longitudinal associations of body adiposity markers with 
intraocular pressure 
To assess the cross-sectional association of body adiposity markers with intraocular 
pressure (IOP) at baseline, as well as the longitudinal association between changes in adiposity 
markers (body mass index, waist circumference, percent fat mass) and IOP over time, we 
developed linear mixed models for longitudinal paired-eye data using a three-level hierarchical 
approach.1, 2 At the first within-eye level, the change in IOP levels Yijt from baseline visit t = 0 
to follow-up visits t = 1,…, mi for eye j = 1, 2 of participant i = 1,…, n was related to the 
corresponding changes in the adiposity marker xit and other subject-specific time-varying 
covariates zit through the linear model 
 Yijt = ij0 + ij1(xit  xi0) + ij2(zit  zi0) + ijt, 
where ij0 was the expected baseline IOP for eye j of participant i; ij1 was the expected 
change in IOP over time for eye j of participant i per unit change in the adiposity marker; ij2 
were the expected longitudinal IOP slopes for that eye associated with the other time-varying 
covariates, including age (continuous), IOP measurement time (morning or afternoon), 
smoking status (never, former, or current), alcohol drinking (< 1, 1–3, or > 3 days/week), 
physical activity (none, 1–3, or > 3 times/week), heart rate (continuous), hypertension (yes or 
no) and diabetes (yes or no); and the within-eye errors ijt were assumed to be independent and 
normally distributed with mean 0 and constant variance 2. 
The second level represented the variation in coefficients ij0, ij1, and ij2 between 




between each participant’s eyes, whereas the longitudinal IOP slopes for the adiposity marker 
ij1 and the other time-varying covariates ij2 were assumed to be fixed for both eyes. Thus, the 
second-level model was 
 ij0 = i00 + bij0, 
 ij1 = i10, 
 ij2 = i20, 
where the between-eye variations within a subject bij0 were assumed to be independent 
and normally distributed with mean 0 and constant variance 2. The longitudinal slopes 
associated with body adiposity markers ij1 were specified as fixed at eye level because 
preliminary analyses showed virtually null random variation in longitudinal IOP slopes 
between each participant’s eyes. 
Finally, the third level described the variation in parameters i00, i10, and i20 across 
participants. The subject-specific baseline IOP i00 was linearly related to each participant’s 
baseline levels of the adiposity marker xi0 and time-varying covariates zi0, as well as to other 
time-constant covariates wi, including sex (female or male), study center (Seoul or Suwon), and 
height (continuous). The subject-specific longitudinal IOP slopes for the adiposity marker i10 
were allowed to vary randomly across participants, while the longitudinal slopes for the other 
time-varying covariates i20 were assumed to be constant for all participants. Specifically, the 
third-level model was 
 i00 = 000 + 001xi0 + 002zi0 + 003wi + bi00, 
 i10 = 100 + bi10, 




where the between-subject variations bi00 and bi10 were assumed to follow a bivariate 
normal distribution with mean 0 and constant variance-covariance matrix V. Combining the 
three nested models, we obtained the linear mixed model 
 Yijt = (000 + bi00 + bij0) + 001xi0 + 002zi0 + 003wi 
  + (100 + bi10)(xit  xi0) + 200(zit  zi0) + ijt, 
which included two nested random effects for the intercept, as well as a random effect 
at subject level for the longitudinal slope associated with the adiposity marker, to account for 
correlations arising from both paired-eye data and repeated measurements over time.3 
In this mixed model, the first line on the right-hand side represented the cross-sectional 
association of the adiposity marker with IOP at baseline. In particular, the fixed effect 001 
corresponded to the mean difference in baseline IOP per unit increase in the baseline adiposity 
marker adjusted for baseline covariates. To allow for nonlinear cross-sectional relationships, 
we modified the fixed-effects specification for xi0 to compare the mean baseline IOP across 
quartiles of the baseline adiposity marker, as well as to estimate smooth baseline IOP changes 
as a restricted quadratic spline function of the baseline adiposity marker with knots at the 5th, 
50th, and 95th percentiles.4 
The second line of the above linear mixed model represented the longitudinal 
association of within-subject changes in the adiposity marker and IOP over time.5 Specifically, 
the fixed effect 100 corresponded to the mean change in IOP over time per unit increase in the 
within-subject adiposity marker adjusted for baseline and time-varying covariates. To assess 
nonlinear longitudinal effects, we alternately replaced the linear term xit  xi0 in the above 
model with quartile indicators and restricted quadratic splines for within-subject changes in the 




baseline. Quartile indicators and linear spline terms were specified as random at subject level to 
allow for random between-subject variations around the average nonlinear longitudinal trend.  
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SUMMARY OF FINDINGS 
Studies on the association of cardiovascular risk factors with IOP and POAG have been 
profuse but inconsistent. Diabetes, for instance, has been proposed as a risk factor for elevated 
IOP, but the association between diabetes mellitus and glaucoma is still controversial. 1–4 A 
meta-analysis published in 2004 concluded that diabetes mellitus was positively associated 
with glaucoma.5 However, this meta-analysis was based only on cross-sectional or case-control 
studies bud didn’t include longitudinal prospective studies and therefore subject to temporality 
bias. Similarly, the literature on the association between BP and POAG is limited and 
inconsistent.2,6–8 Qualitative reviews have summarized the evidence on BP, IOP and 
glaucoma,9–11 but quantitative estimates of the associations were lacking.  
The association between age and IOP is also debatable subject. Cross-sectional and 
longitudinal studies have shown that IOP increases with age in Western populations.12–15 On 
the contrary, cross-sectional studies in the Asian populations reported an inverse association 
between age and IOP,16,17 while one longitudinal study in Japan arrive at an opposite 
conclusion.18 The inconsistencies of these studies could be due to limited sample sizes or to 
methodological issues related to the analysis of the longitudinal IOP trajectories.  
This dissertation adds to the ophthalmologic evidence by 1) systematically and 
quantitatively synthesize available literature on the association of high blood pressure, diabetes 
with IOP and POAG in the general populations; 2) Evaluating the influence of age on IOP in a 
longitudinal cohort study with a large sample of Korean adults; and 3) Evaluating the 
association between baseline and change in body adiposity with the baseline and change in IOP 




In the first chapter, we conducted a systematic review of the available literature on the 
association between blood pressure levels and hypertension with primary open-angle glaucoma 
and intraocular pressure endpoints. Based on the sixty observational studies included in the 
final meta-analysis, we found consistent association between high blood pressure with 
increased IOP and higher risk of POAG. The pooled relative risk for primary open-angle 
glaucoma comparing patients with hypertension to those without hypertension was 1.16 (95% 
CI= 1.05-1.28), with modest heterogeneity across studies (I2 34.5%). Virtually all studies 
reported a positive association between blood pressure and intraocular pressure. The pooled 
average increase in IOP associated with a 10 mmHg increase in SBP was 0.26 mmHg (95% CI 
0.23 – 0.28, I2 30.7%), and the average increase associated with a 5 mmHg increase in DBP 
was 0.17 mmHg (95% CI 0.11 – 0.23, I2 90.5%). 
In the second chapter, we conducted another systematic review of the available 
literature on the association of diabetes and blood glucose levels with glaucoma, intraocular 
pressure (IOP) and ocular hypertension in the general population. We found that diabetes, 
diabetes duration, and fasting glucose levels were associated with a significantly increased risk 
of glaucoma, and diabetes and fasting glucose levels were associated with slightly higher IOP. 
The pooled relative risk for glaucoma comparing patients with to those without diabetes was 
1.48 (95% CI 1.29 – 1.71), with significant heterogeneity across studies (I2 82.3%, p < 0.001). 
The risk of glaucoma increased by 5% (95% CI 1 – 9%) for each year since diabetes diagnosis. 
The pooled average difference in IOP comparing patients with to those without diabetes was 
0.18 mm Hg (95% CI 0.09 – 0.27, I2 73.2%), while the pooled average increase in IOP 
associated with an increase in 10 mg/dL in fasting glucose was 0.09 mm Hg (95% CI 0.05 – 




In the third chapter, we conducted a cross-sectional analysis of 3,299 adults from 2005-
2008 NHANES, to investigated the association between diabetes, pre-diabetes, metabolic 
syndrome and its components and the levels of fasting glucose, HbA1c and HOMA-IR with the 
prevalence of glaucoma. We found that diabetes was strongly associated with prevalent 
glaucoma. In fully adjusted models, the odds ratio for glaucoma comparing participants with 
diabetes with participants in the reference group with neither pre-diabetes nor diabetes was 2.12 
(95% CI: 1.23, 3.67).  The corresponding odd ratio comparing participants with pre-diabetes to 
those in the reference group was 1.01 (95% CI: 0.57, 1.82). Finally, patients with 5 or more 
years of diabetes duration had an OR for glaucoma of 3.90 (95% CI: 1.63, 9.32) compared with 
patients with <5 years of diabetes duration. 
In the fourth chapter, we examined the longitudinal association between age and IOP in 
a prospective cohort study of 274,064 adult men and women who underwent a screening 
examination between January 2011 and December 2013 at the Kangbuk Samsung Total 
Healthcare Center in Seoul and Suwon, South Korea. The average longitudinal change in IOP 
per one-year increase in age was -0.066 mm Hg (95% CI -0.068 to -0.063), with marked sex 
differences (P < 0.001). In men, the average annual IOP change was -0.094 mm Hg (95% CI -
0.096 to -0.091) throughout follow-up. In women, the average annual IOP change was -0.006 
mm Hg (95% CI -0.010 to -0.003), with a relatively flat association in the middle-age range of 
30–59 years and more marked annual decreases at younger and older ages.  
In the fifth chapter, we examine the longitudinal and cross-sectional associations 
between body mass index (BMI), waist circumference, percent fat mass and IOP in Korean 
adults who participated in annual or biannual health examinations. The average longitudinal 




was 0.181mmHg (95% confidence interval [CI] 0.171 to 0.190), 0.269 mmHg (95% confidence 
interval [CI] 0.253 to 0.284) and 0.100 mmHg (95% confidence interval [CI] 0.090 to 0.110), 
respectively, with marked sex differences (P < 0.001). In addition, the average cross-sectional 
differences in baseline IOP per interquartile increase in baseline BMI, waist circumference and 
percent fat mass were 0.393 mmHg (95% CI 0.379 to 0.407), 0.434 mmHg (95% CI 0.412 to 
0.456 mm Hg), and 0.428 mmHg (95% CI 0.410 to 0.445 mm Hg). 
IMPLICATIONS AND FUTURE RESEARCH 
Our research suggested a consistent and robust association between blood pressure and 
IOP.  A significant association between hypertension and POAG was also identified, although 
there was significant heterogeneity across study designs. In addition, diabetes, diabetes duration, 
and fasting glucose levels were associated with a significantly increased risk of POAG, and that 
diabetes and fasting glucose levels were associated with increased levels of IOP. Our study also 
indicated that in a large cohort of Korean adults, IOP decreased with age but the decline was 
stronger in men compared with women and in participants <30 years of age compared with 
older participants. Furthermore, in this population, excess adiposity was associated with 
significantly increased IOP, independent of conventional cardiovascular risk factors including 
hypertension and diabetes. The decrease in body adiposity levels had a greater impact on IOP 
reduction in men than women, and BMI and waist circumference were better longitudinal 
predictors for IOP vs. percent fat mass.  
These findings added to the growing body of evidence suggesting that cardiovascular 
disease risk factors may be important determinants for elevated IOP and glaucoma. 
Hypertensive and diabetic patients should be screened for elevated IOP and higher risk for 




Additional prospective studies are needed to firmly establish the role of blood pressure in 
glaucoma development. There was a relative lack of research on the association between 
glucose biomarkers, prediabetes and metabolic syndrome with glaucoma. Given the high 
prevalence of these metabolic abnormalities, future studies should target this area of research to 
fully understand the implications of altered glucose metabolism on glaucoma risk. In addition, 
patients with elevated weight, or normal weight but excess central adiposity, could be identified 
and referred for eye screening. Clinical trials are needed to establish the role of weight 
management in IOP reduction among obese patients, or patients with normal-weight central 
obesity.  Additional research could also aimed at better understanding heterogeneous effects by 
sex, the underlying mechanisms between cardiovascular risk factors with IOP and POAG, and 
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